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PERSPECTIVES 
 
 
In the academic year 2005/2006 I had the possibility to participate in the Erasmus 
exchange program. I was offered the opportunity to carry out a diploma thesis project 
in the research group of Professor Pellicciari at the University of Perugia.  
Within one of the research topics of this group my thesis project should be dedicated 
to synthesis of new derivatives of Curcumin. Unfortunately, upon starting 
experimental work it was recognized that a strong allergic reaction affected my state 
of health in a way making it impossible to continue the experiments. Professor 
Pellicciari kindly proposed to change the topic of the thesis project from the synthesis 
of novel Curcumin derivatives to a theoretical surveil of the to date important 
synthesized derivatives and the synthesis of Curcumin. Furthermore biological 
activities of the respective compounds and the connection so far proposed between 
the structure and its influence into the pathogenesis of Alzheimer´s disease should 
be investigated.  
Therefore in this work the most important facts about AD, the influence of Curcumin 
in the pathogenesis so far proposed, its origin and chemical structure and as 
mentioned the SAR of some selected derivatives are ascribed. 
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1. INTRODUCTION 
 
 
In this part an overview is given about the most important facts in respect of 
Curcumin,  its origin and use and the idea why it could be benefitial in AD.  
Curcumin has been used in the form of turmeric, the so called powder of the rhizome, 
as an antioxidant food preservative, as an anti-inflammatory turmeric extract and has 
also been widely employed in traditional Indian medicine.1 Curcumin, in particular, 
exhibits plenty of  biological properties.2,3  
Seven major species of Curcuma 
(Zingiberaceae) including Curcuma 
longa Linn., C. xanthorriza Roxb., C. 
wenyujin Y.H. Chen and C. Ling, C. 
sichuanensis, C. kwangsiensis, C. 
aeruginosa Roxb., and C. elata Roxb., 
are cultivated in tropical regions of 
Asia, and Curcumin is the major yellow 
pigment isolated from the ground 
rhizome of Curcuma longa Linn.1 
Ethnologically Curcuma longa 
occupies an important position as 
nearly every food contains in India, and 
religious ceremonies always make use 
of the rhizome powder, called as 
mentioned turmeric, in any form.  
 
The rhizome is normally used for colouring and flavouring food, but as a powder it is 
also used for medical purposes.1,3 In old Hindu texts it is ascribed for its aromatic, 
stimulant and carminative properties. A locally applied mixture of turmeric with slaked 
lime is known as a household remedy for the treatment of sprains and swellings 
caused by injury.1 Current traditional Indian medicine claims the use of turmeric 
against biliary disorders, anorexia, coryza, cough, diabetic wounds, hepatic 
disorders, rheumatic diseases and sinusitis.4  
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Traditional medicine in China uses Curcuma longa for diseases which are associated 
with abdominal pains and icterus.3,5  It has been used for centuries in India and 
elsewhere as a dietary spice and as a herbal medicine for treatment of wounds, 
jaundice, and rheumathoid arthritis and has been shown as non-toxic.1 
It has been reported to be able to confer significant protection against neurotoxic and 
genotoxic agents, and therefore is thought to be able to decrease the oxidative 
damage and inflammation associated with Alzheimer´s disease (AD). Among the 
neurodegenerative diseases AD represents the most common and devastating 
disorder of human brain and is due to a multiple cascade, including crucial events 
such as oxidative damage and chronic-inflammation caused by amyloid-β 
aggregation.6-10 In this connection, it has strongly been suggested that antioxidant, as 
well as anti-inflammatory or combined anti-oxidant/NSAIDs therapies may prove 
useful for AD prevention or treatment.11 After extensive research in the last years 
NSAIDs in particular have entered the therapeutic practice 6, 12, 13 while antioxidants 
are currently being evaluated in order to elucidate their beneficial properties in 
decreasing Aβ-aggregation.14 The yellow curry spice Curcumin reported to be 
endowed with both antioxidant and anti-inflammatory properties may substantiate 
particularly promising for AD treatment. It has also been observed that Curcumin is 
structurally related to Congo Red, a dye known to bind amyloid-β oligomers and 
fibrils in vitro.15 Unlike the negatively charged Congo Red which is both toxic and 
unable to cross the blood-brain barrier, Curcumin´s nature might allow it to enter 
brain and is not as toxic.16 Recent reports, moreover, have shown statistics in which 
the percentage of AD in 80 years old population in India is only a quarter compared 
to that in the US.17  
The idea was to compile literature relating to the most interesting derivatives of 
Curcumin, the synthesis of the compound and its derivatives and the influence in the 
pathogenesis of AD. Therefore a brief overview to the pathogenesis is given as well  
in chapter 2.       
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2.    ALZHEIMER´S DISEASE 
 
2.1. Pathogenesis of AD 
 
2.1.1. Pathophysiological and Clinical Principles of AD 
 
Alzheimer´s disease (AD) is a neurodegenerative disorder presenting the most 
common form of dementia in the elderly population18 and can be divided into an early 
onset type (onset < 60 years) and in the more common late onset type (onset > 60 
years).19 It is currently not possible to predict the onset of AD before the first signs of 
cognitive decline appear.9 
The disease usually begins with gradual failure of recent memory, with preserved 
alertness and motorfunction and progresses slowly to involve many cognitive 
spheres and shortens life expectancy, with most patients ultimately dying of 
secondary respiratory complications.9 The aetiological events leading to AD 
pathogenesis are not clear and although age and the inheritance of predisposing 
genetic factors appear to play a major role, more recent evidence suggests that the 
development and progression of AD is subject to a wide variety of both 
environmental and genetic modifiers.  
 
 
 
 
 
 
 
 
 
Fig. 1   Schematic representation of the events leading to dementia of the Alzheimer´s disease. 
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There is no single gene that accounts for AD heritability, despite some clues that 
have been provided by genetic analysis of rare cases of early-onset familial 
Alzheimer´s disease (FAD) which are caused by missense mutations in the amyloid 
percursor protein (APP) and presenilin-1 and -2 (PS1 and PS2) genes. The vast 
majority of late-onset AD cases are spontaneous (also called sporadic AD). 
Mutations and polymorphism in multiple genes are likely to contribute to sporadic AD 
pathogenesis together with non-genetic factors. There is plenty of evidence that the 
pathology of AD involves amyloid-β (Aβ) accumulation which leads to numerous 
extracellular neuritic (amyloid) plaques and intracellular neurofibrillary tangles (NFTs) 
in the hippocampus, amygdala and association neocortex, oxidative damage and 
neuroinflammation.9, 16, 20 The inflammatory response promoting and substaining 
compounds found in AD brain includes besides the β-amyloid protein the pentraxins 
C-reactive protein and amyloid P complement proteins, the inflammatory cytokines 
interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosisfactor-α, the protease 
inhibitors α-2-macroglobulin and α-1-antichymotrypsin and the prostaglandine 
generating cyclooxygenases COX-1 and COX-2.7 
The presence of chronic neuroinflammation as in AD also appears in other 
neurodegenerative disorders including Parkinson´s disease (PD) and Creutzfeld-
Jacob disease (CJD).12 In the last years of intensive research it has been elucidated 
that the specific accumulation of neurotoxic amyloid-β (Aβ) derived from the 
proteolysis of APP in the central nervous system (CNS) appears to represent a major 
pathological step in the progression of AD.21 Since Aβ accumulation in the form of 
senile plaques has been recognized as one of the major potential causes of AD 
pathology,22 β-amyloid protein, its percursor and metabolism have become the 
subjects of intensive studies to find new targets for novel therapeutic methods and 
prevention of AD. 
 
Currently the treatment of the dementing symptoms of AD is restricted to two types of 
drugs: acetylcholinesterase inhibitors (for example Donezipil) and the N-methyl-D-
aspartate receptorcomplex antagonist Memantine.9 As these drugs only temporarly 
relieve some symptoms for a period of time and do not address the pathologic 
process or substantially slow clinical progression there is a need to develop new 
potential disease-modifying treatments.  
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2.1.2. The AAP and its Cleavage 
 
As mentioned a major cause of AD is thought to be the Aβ-accumulation and the 
resulting formation of amyloid plaques and neurofibrillary tangles. Accordingly, in the 
last years research effords have been directed to the elucidation of crucial aspects of 
the production and the deposition of the β-amyloid peptide. Aβ is derived from the 
larger amyloid percursor protein ( APP)23-25 which is encoded by a single gene on 
chromosome 21.26, 27 APP presents an ubiquitously expressed type 1 membrane 
glycoprotein27 with a single transmembrane domain, a large extracellular domain 
(ectodomain, N-terminal region) and a short cytoplasmic (C-terminal) tail  
(Fig. 2).25, 26 
 
 
 
 
Fig. 2  The Amyloidpercursorprotein. 
 
 
The function of APP is unknown, but roles in maintaining metal homeostasis, cell 
viability and blood hemostatis have been confirmed.28 By alternative splicing of a 19-
exone gene - which represents APP - multiple isoforms are obtained ranging from 
563 to 770 amino acid residues.26 Aβ is derived from the region of the protein 
encoded by parts of exons 16 and 17 and the predominant transcript isoform 
APP770 containing exon 7 domain which also contains a serine protease inhibitor 
called Kunitz proteinase inhibitor (KPI).20 Cleavage of APP is complex and can occur 
via several different routs, which have been categorized as either amyloidogenic or 
nonamyloidogenic pathway. In particular it is processed by three proteases 
designated as α-, β- and γ-secretase.24, 25 Cleavage by either α- or β-secretases 
produces large soluble N-terminal fragments (sAPPα and sAPPβ), C83 and C99 
membrane-bound C-terminal fragments, respectively and further cleavage by γ-
secretase releases non pathogenic p3 peptide, a truncated Aβ fragment27 and Aβ  
(Fig. 3).20 
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Fig. 3  Schematic diagrams of the amyloid precursor protein (APP) and its metabolic derivatives. The largest APP isoform is 
APP770 (shown centre) with a large extracellular domain and short intracellular segment. The drawing is not to scale; the 
transmembrane region has been magnified to permit clear visualisation of the cleavage events. SP represents the signal peptide 
and KPI the Kunitz proteinase inhibitor domain. 
 
 
α-Secretase cleaves APP within the Aβ region20 and is usually considered as non-
amyloidogenic cleavage because it does not produce Aβ.26 However, its product p3 
is sometimes found in plaques. Some representatives of the family of disintegrin 
metalloproteases (or adamlysines) have been postulated as α-secretase candidates 
like TACE (also called tumor necrosis factor alpha (TNF-α)), ADAM-10                  
and MDC-9.20, 23, 26 All members display a common domain organisation and possess 
four potential functions: cell fusion, cell adhesion, intracellular signaling and 
proteolysis.20  
β-Secretase corresponds to the alternative amyloidogenic pathway and cleaves APP 
at the β-cleaving site at the APP ectodomain generating membrane bound C-terminal 
fragments20, 23 and Aβ peptide is left anchored in the membrane with a free N-
terminus.116 Two aspartyl protease homologues BACE and BACE-2 were recently 
identified to cleave APP at the β-secretase sites.20, 29  
γ-Secretase cleavage represents the critical step because fragments resulting from 
α- and β-secretase cleavage remain anchored in the membrane and may become 
degraded or further processed by γ-secretase26 to form p3 (non toxic) and Aβ 
(including Aβ42, that is associated with AD pathogenesis).20 The integrity of γ-
secretase remains elucidative but it has been evaluated that the presenilins PS1  
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and PS2, which were initially discovered through genetic analysis of early-onset  
FAD, are two candidates for catalytic components of γ-secretase. 20, 26, 30 Recent 
studies have shown that γ-secretase is a more complex entity than preseniline alone 
and that nicastrin interacts strongly with the presenilins, co-immunoprecipitates with 
APP C-terminal fragments in the context of presenilin FAD mutations and deletion of 
specific regions within the nicastrin molecule. This leads to significantly reduced Aβ-
production.20 The overall structure of α-, β-, γ- secretase-like proteins are depiced in 
Fig. 4. 
 
 
 
 
 
 
Fig. 4  Domain organisation of membrane bound APP, one of the α-secretases (TACE), β-secretase (BACE1), presenilin-1 and 
nicastrin. The two aspartic acid residues in transmembrane domains 6 and 7 of PS1 are shown as stars. Abbreviations: SP: 
signal peptide, KPI: Kunitz proteinase inhibitor domain, CAT: catalytic domain, CYS: cysteine rich domain, PRO: prodomain 
(also called inhibitor domain), CYT: cytoplasmic domain, CRAM: crambin-like domain, T: transmembrane region. 20 
 
 
 
 
Despites the recent findings the physiological functions of APP are poorly 
understood.  
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2.1.3. The Biology of β-Amyloid 
 
Aβ is a peptide of 39-43 amino acids,23 that is heterogeneous at both its amino and 
its carboxyl termini,19, 31  attributed to differences in local tissue processing and Aβ is 
also found at low concentrations as a normal constituent of biological fluids.31 The C-
terminus determines the rate of fibril formation and the N-terminus is necessary for 
polymerization.25 The cleavage of APP gives rise to mainly two different types of Aβ: 
the solubile sAβ (predominantly Aβ1-40) and the Aβ (Aβ1-42) which is found in 
amyloid deposits.19 The length of Aβ-peptide dramatically influences its physical 
properties and it has been evaluated that the longer forms which end at position 42 
(Aβ42) and 43 are more amyloidogenic 25 because of the presence of Leu41 and 
Val42 at the C-terminus,32 which also has been suggested to be particularly important 
for the initiation of Aβ deposits and cytotoxicity.19  
The difference between sAβ and Aβ is caused by many different factors including 
mutations. Soluble Aβ is predominantly a random coil and a α-helical folded 
peptide,25 whereas the insolubile Aβ has a predominantly toxic β-sheet content, 
consisting of two β-sheet domains spanning residues 10-25 and 30-42.32 This β-
sheet conformation is associated with its relative insolubility, its resistance to 
degradation19, 25 and its ability to form fibrillar or amorphous deposites which 
compromise neuritic and diffuse plaques, respectively.25 Fibrillogenesis can be 
modulated by lipoproteins, glycosaminoglycanes and metals. The apolipoprotein E 
molecule (apoE2, E3, E4), which bind to Aβ and ApoE4, is a another risk factor, 
which lowers age of onset by presumably altering Aβ aggregation.28  
Aβ is also able to stimulate inflammatory response from microglia, to inhibit neurite 
outgrowth, activate protein phosphorylation and is neurotoxic.28 It was shown that low 
concentrations of Aβ are neurotrophic33 leading to the suggestion that disruptions of 
Aβ generation, as occurs in AD, may be replacing a trophic activity with a toxic one.25  
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2.1.4. The Role of Aβ and Other Associated Factors in AD  
 
The pathogenesis of AD is complex and is driven by both environmental and genetic 
factors. Although most of the cases are sporadic with an obscure etiology, some of 
the disease are inherited and several genes were found to be clearly implicated in 
familial Alzheimer´s disease (FAD).10  
To the early onset inherited forms three genetic loci are linked and found in the 
genes encoding for the APP, presenilin-1 (PS1) and presenilin-2 (PS2) and a genetic 
risc factor for developing late-onset dementia represents the inheritance of the ε4 
allele of apolipoprotein E.34 
 
 
Chromosome Gene Defect Phenotype 
 
     21 
 
β-Amyloid-percursor-
protein mutations 
Increased production of all      
β-amyloid proteins or 
β-amyloid protein 42 
 
     19 
 
ApolipoproteinE4          
polymorphism 
Increased density of 
β-amyloid plaques and 
vascular deposits 
 
     14 
 
Presenilin 1 mutations 
Increased production of 
β-amyloid protein 42 
 
       1 
 
Presenilin 2 mutations 
Increased production of 
β-amyloid protein 42 
 
 
Table 1  Genetic factors predisposing to AD: Relationship to the β-Amyloid phenotype.
9
      
 
 
From the neuropathological perspective, the major hallmarks of AD is the presence 
of two characteristic lesions: the senile amyloid plaques (SP)35 – extracellular 
insolubile congophilic protein aggregates composed of amyloid β8 - and 
neurofibrillary tangles (NFTs)35 –intracellular lesions consisting of paired helical 
filaments (PHFs) from hyperphosphorilated cytoskeletal protein tau.8 It has been a 
longstanding debate whether they are essential components in the pathogenetic 
process or only markers of nerve degeneration, but since it has been evaluated that 
autosomal dominant mutations in the gene encoding the APP were causal for  
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early-onset familial AD (FAD), it is strongly suggested that Aβ plays a primary role in 
the pathogenesis.8 As mentioned currently 4 genes in which mutations or 
polymorphisms cause Alzheimer´s disease have been confirmed (shown in table 1) 
and additional candidate genes await confirmation. Thus because the 
apolipoproteinE4 allele is a normal genetic polymorphism that confers an increased 
risk (but not certainity) of AD, it is indicated that genetic factors predisponding to the 
disease do not need to occur in a dominant pattern and may thus be hard to 
recognize in genetic epidemiological studies.9 All identified mutations cause 
increased formation of total Aβ or, specifically, the more fibrillogenic Aβ1-4235 and 
lead to excessive accumulation of Aβ42.10 Therefore, they support the amyloid 
cascade hypothesis, which is formed by the basis that APP participate in neuronal 
cell death in AD forms.35 Besides all debates Aβ is proposed as central trigger of 
pathological changes as synapse loss, activation of inflammatory process, the 
induction of neurofibrillary changes leading to formation of PHF and ultimately 
neuronal death as shown in scheme 1. 8 
 a) 
               
 
 
 
Scheme 1  Illustration of the amyloid cascade hypothesis. (a) After processing of APP by β- and γ-secretase, Aβ is secreted 
and (b) aggregates into fibrils that deposit in senile plaques. Fibrils and plaques can induce neurotoxicity.8 
 
 
Other evidences for the amyloid hypothesis derive from numerous studies. It is 
proposed that additional factors may be as important as Aβ in the pathogenesis of 
AD and that the cascade hypothesis is an oversimplification.19 Nevertheless the 
amyloid theory remains still  controversial because of the weak correlation between 
the amyloid load and several parameters of neurological dysfunction.10  
However, it is widely believed that the progressive accumulation of Aβ-aggregates 
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is fundamental to the initial development of neurodegenerative pathology and triggers 
a cascade of events as neurotoxicity, oxidative damage and inflammation that 
contribute to the progression of AD.16, 34 Nevertheless it remains elucidative how the 
senile plaques and neurofibrillar tangles are built and the influence of the metabolites 
and mutations found so far in the development of the pathogenesis. Furthermore, 
which microglial products, alone or combinatorially, mediate neurotoxic response, to 
find targets for inhibition and novel therapeutic methods. 
 
 
 
2.2. Therapeutical Approaches in AD 
 
2.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in AD 
 
Before discussing the potencies of Curcumin in AD the influence of NSAIDs in the 
pathogenesis should be avowed. On one hand because Curcumin is also thought to 
exhibit NSAIDs properties and on the other hand because NSAIDs are currently used 
as therapeutic methods in AD. 
As we know, the major cause of neurotoxicity in AD pathology is represented by the 
deposition of β-amyloid into insoluble plaques, and fibrillar peptide formation and 
deposition caused by mutations in the gene encoding the APP, and that the 
presenilin genes are key events in the pathophysiology.9, 34, 36  Now we are focusing 
on the other hallmark of AD, the inflammatory event that occurs in the brain as a 
response to the extracellular deposition of Aβ-fibrils.37 The primary immune effector 
cell responsible for this inflammatory part of the disease is the microglial cell. 128 The 
microglial respond to the deposited amyloid fibrils and plaques exhibits enhanced 
expression of a variety of cell surface proteins, and the consequence of microglial 
activation is a fulminating process resulting in the astrogliosis and neuronal cell death 
that also characterizes the pathology of the AD brain.38-40 The activated microglia 
secretes a diverse range of acute-phase proteins and complement components, 
notable is the secretation and synthetis of the proinflammatory cytokines interleukin-
1β (IL-1β), IL-6, and tumor necrosis factor α (TNFα) and the chemokine macrophage 
chemotactic protein-1. This appearance of inflammatory products in the AD brain has 
been interpreted as evidence of a chronic inflammatory component in the 
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diseaseprocess, and has led to studies exploring the effect of anti-inflammatory drug 
treatment on the incidence of AD-related dementia.41 This concept is favoured by 
epidemiological studies of patients with arthritis, where it was shown that there is a 
reduced risk of AD when consuming NSAIDs for treatment39 and numerous studies 
support the finding that chronic intake of nonsteroidal anti-inflammatory drugs 
(NSAIDs) can decrease risk for AD by more than 50%.13, 38  
 
 
2.2.1.1. Nonsteroidal Anti-inflammatory Drugs 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of pharmacologically 
related compounds with analgetic, antipyretic and anti-inflammatory properties. Their 
shared characteristics is inhibition of cyclooxygenase (COX) enzymes. In low to 
moderate doses NSAIDs act centrally to inhibit fever and pain. Higher doses inhibit 
local inflammation by blocking the induction of interleukin-1 (IL-1), interleukin-1β (IL-
β) and possibly IL-6 via pathways that rely on prostaglandin synthesis. 7 
 
 
 
2.2.1.2. The Influence via Cyclooxygenases 
 
The anti-inflammatory actions of NSAIDs and their therapeutic benefit in treating AD 
have been attributed to the ability of these drugs to inhibit the cyclooxygenases which 
are the rate limiting enzymes responsible for the conversion of arachaidonic acid into 
inflammatory mediators, including prostaglandine E2 (PEG2).38 Two enzyme 
isoforms, COX-1 and COX-2, have been identified in the brain and periphery. These 
two forms are encoded by distinct genes on different chromosomes, but share 
approximately 80% sequence homology and have similar catalytic activity. COX-1 is 
constitutively expressed by many cell types, while COX-2 is induced at sites of local 
inflammation.7 Therapeutic benefits of NSAIDs are typically observed at doses much 
higher than those required to inhibit the cyclooxygenases, that suggested that there  
e other targets of NSAIDs  action,42 and also because it became apparent that only  
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a subset of NSAIDs lower Aβ42 levels, whereas all NSAIDs by definition inhibit  
COX.13 Furthermore, it was demonstrated that the effects of non-selective NSAIDs 
differ from that of COX-selective compounds, and also COX-1 and COX-2-selective 
compounds differently affect Aβ40- and Aβ42 secretation. The elucidation of the 
acting mechanism of NSAIDs is of great interest also because prolonged treatment 
with existing NSAIDs results in severe side effects. Most prominently in the 
gastrointestinal tract, that occur primarily as a consequence of the inhibition of COX-
1 activity38 and actually the benefits of NSAIDs in AD are still a matter of debate. To 
date two strategies to overcome the gastrointestinal side-effects have been identified. 
One is the use of the R-enantiomer of flurbiprofen, which maintain the Aβ-lowering 
properties without causing gastric damage because of lacking COX-inhibition43 and 
the other is based on using the NO-releasing derivatives of flurbiprofen which have 
been shown to reduce brain inflammation and Aβ-burden.44 Nevertheless further 
biological and clinical investigations should be done to clarify the mechanism of 
NSAIDs in AD and whether the mentioned strategies will lead to innovative and 
effective treatment options. 
 
 
 
2.2.1.3. Influence via PPARγ 
 
Another study provided evidence that the mechanism by which NSAIDs intervene in 
disease progression could be their capacity to act as agonist for PPARγ and alter, at 
the transcriptional level, microglial production of proinflammatory products. The 
PPARs are a class of nuclear receptor superfamily members called termed 
peroxisome proliferator-activated receptors (PPAR). They are lipid-activated DNA-
binding proteins structurally related to the steroid and retionic acid receptor families 
and are associated with sequence-specific promoter elements and transcriptionally 
regulate gene expression after ligand binding.45 There are three isoforms (PPARα,-γ 
and δ) which are differently expressed. The natural ligands for this receptor family 
are fatty acids and metabolites38 and has well described roles in adipocytes and 
serves to regulate enzymes of lipid metabolism in these cells.38 It was found that the 
PPARγ isoform is expressed in monocytes and macrophages in which its principal 
action is to suppress the expression of proinflammatory cytokines IL1-β, 
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TNFα, and IL-6 and other proinflammatory products. The natural ligand of PPARγ is 
the J class prostaglandine PGJ2 (15d-PGJ2) and its immediate metabolites and its 
activation affects negatively the macrophage activation and cytokine expression by 
antagonizing the activity of the transcription factors NFkB, AP-1, and STAT 
proteins.45 The PPARγ isoform can also be activated by indomethacin and other 
NSAIDs42 as the antidiabetic drugs of thiazolidinedione class, as well as the naturally 
occuring fatty acid docosahexaenoic acid (DHA).38 It was reported that PPARγ 
agonists act to inhibit the production of proinflammatory and neurotoxic products 
produced by β-amyloid (Aβ)-stimulated microglial cells and monocytes.38 It was noted 
that therapeutically efficious doses of NSAIDs are achieved at greater concentrations 
than those required to inhibit COX activity42 and that Aspirin, a potent COX inhibitor, 
does not reduce risk of AD. These findings led to the suggestion that NSAIDs also 
act via another mechanism, and particular in AD the potency of these drugs is 
attributed to their ability to act as PPARγ agonist rather than to inhibit COX activity.128 
Because PPARγ agonists are little or non toxic and exhibit a substantial 
bioavailability after oral administration these drugs would offer better agents in 
treating or maybe preventing AD than COX inhibition.38 
 
 
 
2.2.1.4. Via Direct Modulation of γ-Secretase Activity 
 
More recently NSAIDs were suggested to represent a class of compounds which 
lower Aβ42 production by direct modulation of γ-secretase activity or the enzyme 
substrate, i.e. APP.13 In the study of Weggen et al.13 it was shown that some NSAIDs 
which on the one hand do not show the same subtle switch in AB cleavage to 
produce shorter AB peptides than the molecules which were proposed to be γ-
secretase inhibitors, on the other hand exhibit features that are in common with these 
previous evaluated γ-secretase inhibitors. First, NSAIDs lower Aβ42 both in cell-
based assays and in vitro, and notable regarded to this NSAIDs inhibited Aβ42 but 
not Aβ40 in an in vitro γ-secretase assay and second, their ability to reduce Aβ42 is 
altered by PS and APP mutations. The primary evaluated γ-secretase inhibitors 
cleave also substrates such as Notch and ErbB-4 and it is unclear whether inhibition 
of γ-secretase through these molecules can be used clinically without causing  
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serious side effects.46 Considerating that NSAIDs which specially inhibit Aβ42 
production do not appear to affect Notch processing and as mentioned above only 
some NSAIDs inhibit Aβ-formation, complete elucidation of the exact molecular 
mechanism by which NSAIDs lower Aβ generation represents an interesting aspect 
for developing novel Aβ42-specific γ-secretase inhibitors.13 
 
However, also other proposed mechanisms by which NSAIDs are able to influence 
Aβ induced neurotoxicity were discussed, but further investigations are required to 
explore the effects of NSAIDs and their mechanisms in neuronal cells. 
 
 
 
2.2.2. Dyes as Ligands for Attacking Amyloid ? 
 
Various diseases including Alzheimer´s disease are characterized by proteinaceous 
deposits in the affected organs which contain several common elements, among 
them amyloid fibrils.47 Besides the specificity for each disease these amyloid fibrils 
have remarkably similar properties as they all tend to be long (>1 μm), thin (10 – 20 
nm), straight and unbranching. Their internal structure is largely a cross β-sheet and 
the strands which make up the β-sheet are arranged perpendicular to the long axis of 
the fibrils.48 
Various approaches in trying to inhibit the production and reduce the extent of 
accumulation of fibrillar Aβ in the brain are currently being evaluated as potential 
therapies for AD.49-54 It is therefore of great interest to develop ligands that 
specifically bind fibrillar Aβ aggregates. Since extracellular senile plaques (SPs) are 
accessible targets, these new ligands could be used as in vivo diagnostic tools and 
as probes to visualize the progressive deposition of Aβ in studies of AD 
amyloidogenesis in living patients, and therefore maybe potential targets for 
prevention and cure.55 It is widely accepted that Aβ is only toxic when it is aggregated 
and like all amyloid fibrils, Aβ fibrils present two characteristic features. First, amyloid 
deposits observed in tissue sections appear orange under the light  
microscope. Second, amyloid deposits stained with Congo Red (CR) display a green 
birefringence when viewed between crossed polarizers in a light microscope. This 
birefringence is the result of the ordered structure of the amyloid fibrils, which have  
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multiple dye-binding sites with orientation related symmetry.56 Consequently, it was 
tried to evaluate if some of these dyes which are used to vizualize amyloid plaques 
have also the possibility to inhibit or decrease the fibrillation. 
 
 
 
2.2.2.1. Congo Red 
 
Congo Red (CR) is a hydrophilic dye that has an absorption spectrum that changes 
in the presence of proteins with a β-pleated sheet conformation.56 It is widely used as 
a histological dye for staining amyloid163 and in addition to this use as an diagnostic 
agent for amyloidosis CR has been demonstrated to inhibit pathological aggregation 
of the amyloid β-peptide.58 Since this finding experiments were aimed at the 
elucidaion of the molecular mechanism of the CR - amyloid interactions and other 
structurally similar dyes and derivatives were tested for their properties in binding to 
amyloid fibrils as well. This should led to new diagnostic agents with higher amyloid 
specifity and anti-amyloidosis drugs that inhibit amyloid formation and/or solubilize 
already deposited amyloid fibrils.57 The interaction of CR with Aβ became also of 
interest as it was shown that CR when added after Aβ, reverses the Aβ-induced 
effect. This effect could not be explained by the inhibition of Aβ fibril formation and 
therefore revealed a new aspect of the interaction with Aβ.59 Several binding assays 
of CR to polypeptides with known secondary structures indicated that an extensive β-
sheet structure was necessary for CR to bind to polypeptides.60 The affinity of CR for 
amyloid was also proposed to depend on the structure of CR: the two 
aminosubstituted naphthalenesulfonic acid moieties connected by azo linkages to a 
central biphenyl group (Fig. 5) and modifications of the naphthalene ring largely 
effects the affinity for amyloid fibrils. Thus it was suggested that the conjugated rings 
as well as the sulfonic group are involved in the interaction with amyloid.57 
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Fig. 5 The structure of Congo Red.
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The first model of CR binding to fibrillar β-amyloid was developed by Klunk et al. in 
1994 which tried to explain the relative affinities of various CR congeners for the β-
amyloid fibril considering that CR does not bind to a single β-amyloid peptide but 
requires the formation of a β-sheet containing fibril and CR binds with its long axis 
parallel to the fibril axis.61 Thus, the fibrils were never defined precisely by x-ray 
diffraction for the reason of their noncrystalline-insoluble nature another model was 
evaluated. In that model CR was co-crystallized with a protein showing an internal β-
sheet structure. The crystal coordinates of CR bound into the internal β-sheet in 
dimeric insulin were used,15 because of the high amino acid similarity of the porcin 
insulin CR binding site and the residues 15 – 23 (QKLVFFAED) of β-amyloid (Fig.6). 
 
 
 
 
 
 
 
Fig. 6  Sequence alignment of human β-Amyloid peptide 1-42 with porcine insulin β-strand.
15 
 
 
The different conceptions of the alignment of CR to the peptide is demonstrated in 
Fig. 7. (a) is the perpendicular alignment proposed by Klunk et al. 167 and (b) shows 
the parallel alignment of CR to the peptide which was postulated by Carter and  
Chou. 15  
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Fig. 7  Model of alternative CR binding orientation in Alzheimer´s β-amyloid fibril.
15
 
 
 
In Fig. 8a the orientation of the CR molecule in the dimeric insulin structure is shown 
and when the 9 amino acid peptide from insulin, which forms the pseudo β-sheet, is 
substituted with the similar 9 amino acids from human β-amyloid peptide (amino 
acids 15-23) and subjected to energy minimization, structure 8b is obtained and the 
similarity in these figures is evident.15 
 
 
 
Fig. 8   Ball and Stick model of both, porcine insulin β-sheet CR binding site and the model of the proposed structure of CR 
binding to β-amyloid antiparallel β-sheet strands, res. 15 – 23.
15
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Phenylalanine-24 (Phe24) in the insuline peptide seems to interact with the CR ring 
the same way as Phe19 in the β-amyloid chain. In Fig. 9 demonstrating a line 
drawing format of energy minimized structure the common features are as well 
obvious. 
 
Fig. 9  Line drawing model of the insuline peptide.
15
 
 
They replaced the 15 – 23 residue in antiparallel conformation without CR and 
observed significant changes in the structures. The suggested model presents a very 
possible model of CR binding to a simple dimeric form of β-amyloid that plausibly is a 
percursor to the fully formed fibril that may explain the effects of CR binding to β-
amyloid fibrils.15 In that work it was as well proposed that Phe19, due to its similarity 
to Phe24 in porcine insulin and the observation that substitution of Phe19 through 
threonine (Thr) abolish plaque-forming competence is a key in determaining the 
properties of the fibril.62 The interaction of CR with performed fibrils was also thought 
to take place with those antiparallel strands that participate in the formation of the 
surface and ends of the fibrils. Therefore, CR may disturb the interaction of the fibril 
with the plasma membrane, which would explain the decrease of the Aβ-fibril-CR 
complex and its effectivness in both preventing and reversing the effects of Aβ.15, 59   
It was also shown that CR did not decrease the cellular uptake of Aβ and did not 
increase the cellular Aβ secretion. Furthermore, it was indicated that CR could not 
account by itself for the striking rise in Aβ monomer and no evidence of a cell-
associated Aβ-degrading protease inhibitable by CR was found. Regarding all 
mechanisms of the effects of CR, it was speculated that CR binds Aβ monomers and  
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prevents its interaction with other monomers – as competitive antagonist for Aβ59 – 
and/or works together with other factors released by the cells that are capable of 
promoting Aβ polymerization.63 Through explorations where the binding mode of CR 
to Alzheimer´s Aβ peptide by UV Raman spectroscopy was examined, it was oserved 
that the intensity of the UV Raman bands of CR significantly increases upon binding 
to Aβ. This spectral change is in line with that observed when the average molecular 
planarity was increased by crystallization and opposit to that observed when the 
planar conformation of the biphenyl group is inhibited by methylation. Therefore it 
was suggested that in the CR-Aβ complex, the biphenyl conformation may be closer 
to planar than in the unbound CR, and the torsional mobility of the biphenyl group 
may be required in approaching the binding site through the mesh of β-sheet and this 
mobility should also be retained in new derivatives.57 Another approach is based on 
highly conjugated chrysamine-G (CG) (Fig 10) but as both CG and CR are  too large 
(molecular weight > 700), making them unlikely candidates for penetrating the intact 
blood-brain barrier, and therefore, they are not suitable as imaging agents for 
detecting fibrillar Aβ aggregates in patients with AD.55 Potential ligands for detecting 
Aβ aggregates in the living brain must cross the intact blood-brain barrier. In order to 
follow this approach the two derivatives X-34 and BSB (Fig. 10) were designed and 
thought to exhibit strong potencies.32  
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Fig. 10  Structures of CG, XR-34, BSB.
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XR-34 contains instead of the diazo group a simple vinyl group and has several 
advantages over CR and CG because it is smaller, therefore may penetrate intact 
blood brain barrier more readily. The vinyl group improves the in vitro and in vivo 
stability. BSB was shown to bind specifically to Aβ in vitro and specifically to Aβ(1-42) 
aggregates,55 labels Aβ plaques in the sections from AD brains, cross the blood brain 
barrier in Tg mouse models of amyloidosis and labels senile plaques with a 
sensitivity and specificity equal to that of CR.32 
 
 
 
2.2.2.2.  Benzothiazoles Thioflavin S and T and Styrylbenzenes 
 
Research also concentrated on other dyes in purpose to evaluate new small ligands 
that specifically bind fibrillar Aβ aggregates and to improve brain ligands with a 
smaller molecular size and increased lipophilicity than CR and CryG. To generate 
ligands with those properties it was concentrated on highly conjugated thioflavins S 
and T, which are commonly used as dyes for staining the Aβ aggregates in the AD 
brain.64 These compounds are known to bind amyloid specifically. They are based on 
benzothiazole which is relatively small in molecular size. However, the thioflavins 
contain an ionic quaternary amine, which is permanently charged and unfavorable for 
brain uptake. Therefore it was reported that small molecule-based radioiodinated 
ligands, showing selective binding to Aβ aggregates, cross the intact blood-brain 
barrier by simple diffusion. Four novel ligands showing preferential labeling of 
amyloid aggregates of Aβ(1-40) and Aβ(1-42) peptides. Two 125I-labeled 
styrylbenzenes, (E,E)-1-iodo-2,5-bis(3-hydroxycarbonyl-4-hydroxy)- styrylbenzene 
(ISB), and (E,E)-1-iodo-2,5-bis(3-hydroxycarbonyl-4-methoxy)styrylbenzene (IMSB), 
and two 125I-labeled thioflavins, 2-[4´-(dimethylamino)phenyl]-6-iodobenzothiazole 
(TZDM), and 2-[4´-(4´´-methylpiperazin-1-yl)phenyl]-6-iodobenzothiazole (TZPI), 
were prepared at a high specific activity (Fig. 11).64 Using these four radioiodinated 
probes with high specific activity, studies of the binding of the ligands to aggregates 
of Aβ(1-40) and Aβ(1-42) peptides in solution were carried out. All of the ligands 
displayed a saturable binding in vitro and in human brain55 and it was provided 
compelling evidence that there are distinctive and mutually exclusive binding sites on  
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Aβ(1-40) and Aβ(1-42) aggregates for these two series of compounds. 
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Fig. 11  Synthesized styrylbenzenes and thioflavins.
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It is known that if Aβ(1-40) and Aβ(1-42) peptides are aggregated, they assemble into 
a fibrillary coil containing β-sheet structures. It is evident that under the conditions 
used in that work Aβ(1-40) and Aβ(1- 42) peptides form aggregates containing two 
different binding pockets for styrylbenzenes and benzothiazoles (thioflavins). Clearly, 
there are significant structural differences between these two aggregates, and 
additionally at least two different binding pockets, possibly more, exist on these 
aggregates.65, 66 Neither detailed structural information was available on the potential 
binding sites, nor the full extent of functional linkages of these styrylbenzene or 
benzothiazole binding sites on Aβ aggregates was known. It has been suggested 
previously that binding of small molecules to the Aβ aggregates may prevent further 
aggregation and reduce their toxicity.65, 67 Further testing is warranted to investigate 
any functional or physiological roles of these binding sites in amyloid plaque 
(aggregates) formation and cellular toxicity. To test the permeability through the 
intact bloodbrain barrier, these new agents were injected into untreated mice. The 
results suggest that these two styrylbenzenes showed relatively low initial 
permeability on crossing the blood-brain barrier. The potential usefulness of these 
agents for in vivo imaging after a bolus i.v. injection appears to be limited. The 
compounds derived from benzothiazole were prepared to improve the brain uptake 
after an i.v. injection. These compounds are derivatives of thioflavins, but do not 
contain a quaternary ammonium ion; therefore, they are relatively small in size, 
neutral, and lipophilic. It was assumed that thioflavins may provide better candidates 
for further development of the in vivo imaging agents critically important for 
evaluation of Alzheimer’s disease. Nevertheless all of them may be useful as  
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biomarkers for studies of Aβ(1-40) as well as Aβ(1-42) aggregates for detecting 
amyloid aggregates in the brain by in vivo and in vitro techniques.55 Further 
derivatives of styrylbenzene-, and thiovlavin as well as m-I-stilbene have been tested 
and modified to overcome the low brain penetration in a genetically altered 
transgenic mouse mode for AD.68 In that approach it was clearly suggested the 
suitability of the detection of amyloid deposits in the living brain and if these 
derivatives can act as ligands in AD patients it may be possible to detect the Aβ 
plaques in the living human brains by in vivo imaging techniques. A very recent work 
proposes a general binding model for amyloid-specific dyes to amyloid fibrils thruogh 
examinations based on thioflavin T.69 Through observation of spherulites which are 
formed by peptides and proteins under amyloidogenic conditions by confocal 
microscopy using thioflavin-T as the dye and exciting the dye with polarised light a 
consistent pattern was noticed.70 This phenomenon can only occur if thioflavin-t binds 
in a specific orientation with respect to the amyloid fibrils, thus the binding orientation 
can be deduced. Therefore the anisotropic fluorescence emission from amyloid fibril-
containing spherulites in the presence of thioflavin-T indicates that the dye binds in a 
regular fashion to amyloid fibrils. By analyzing the emission intensity as a function of 
the angle between the plane of polarisation of the exciting laser beam and the 
orientation of dye molecules, it was shown that the long molecular axis of the dye 
needs to be parallel to the plane of polarization of the light to be excited. This implies 
that the dye binds to the fibrils with its long axis parallel to that of the fibrils. As 
channels are running in the same direction on the β-sheet of the amyloid fibrils they 
seem likely to act as the binding site of the dye. In Fig. 12 the thioflavin-T together 
with the diagramm of the β-sheet with backbone atoms N, C, Cα and the side chain R 
for one residue is shown. 
S
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Fig. 12   Thioflavin-T and the diagram of a β-sheet.
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This scheme of β-sheet is valid for both parallel and anti-parallel sheets. As part of a 
fibril the long axis of the fibrils would be perpendicular to the surface of the page and 
one of the binding channels is indicated with a double headed arrow. Thioflavin-T is 
therefore thought to bind with its long axis parallel to the long axis of the arrow.69 
 
 
 
Fig. 13 demonstrates a schematic 
representation of a protofilament with, 
arbitrarily, three β-sheets. Individual β-
strands are shown by ´zig-zag´ lines in 
black, dark and light grey. Sidechains 
accessible from the solvent are shown 
as black circles and point out of the 
plane of the paper. Note that 
sidechains on the third, light grey, β-
sheet are also accessible from the 
solvent  and  point  below  the  plane of 
the paper (not shown for clarity).  
 
 
 
 
Fig. 13 Schematic representation of a protofilament 
   with 3 β-sheets.
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Dye molecules are represented by double headed arrows. When several 
protofilaments form a fibril, some of these surfaces will be obscured, resulting in 
impeded dye binding in those areas. The steric constraints imposed by this 
environment are largely unique to amyloid fibrils, offering an explanation for the 
specificity of structural similar dyes.175 The understanding will promote aid for 
developing new derivatives. The dye thioflavin-S has so far not been explored which 
may be due to the fact that thioflavin-S exists as a mixture and is no pure chemical 
entity.71 
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2.2.2.3.    Cyanines 
 
Further intense research in finding new ligands concentrated on Cyanines which 
have also been used as sensors to examine β-sheet structures in solutions and thin 
layers. The cationic, conjugated cyanine dye Pinacyanol chloride (PIN), which was 
proved to be an useful tool in studying the aggregation characteristics of ovalbumin in 
a β-sheet conformation presents an advantage in comparison to CR.178 Its spectral 
changes make it possible to distinguish between aggregated and nonaggregated 
forms or between α and β conformations and it has to be shown two fold more 
sensitiv in Aβ-binding. The interaction between PIN and Aβ is mainly 
electrostatic.Inouye et al.73 found that Aβ has an isoelectric point of 5.5, and at the 
pH used in the study (7.4) the peptide presents a net negative charge due to the 
carboxyl groups of aspartic acid and glutamic acid. Hence, the peptide interacted 
electrostatically with the positive PIN. Such an interaction would be independent of 
the peptide conformation, and it is the motif by which spectral changes produced by 
peptides in an α-helix conformation can be observed. However, there is a factor that 
is related to the β conformation, suggesting that PIN can be used as a probe for 
fibrillar Aβ.72    
 
 
 
 
2.2.3. Curcumin and its Properties in Aβ-Induced Cytotoxicity 
 
Since  this subject represents also a main part of the literature research it is more 
precisely presented in the chapter 4.3 at pages 59 ff. 
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3. METHODS & CRITERIA FOR THE LITERATURE  
RESEARCH 
 
Following data bases were used for the literature research: 
 
 • SciFinder       [http://www.cas.org/SCIFINDER/] 
 • PubMed         [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed] 
 • Elsevier Science      [http://www.elsevier.com/wps/find/journal_browse.cws_home] 
 • Emeroteca Virtuale  [http://www.caspur.it/sitispecialistici/emerotecavirtuale.html] 
 • American Chemical Society                    [http://pubs.acs.org/about.html ] 
 • The New England Journal of Medicine   [http://content.nejm.org/search.dtl] 
 
 
Relating to the subject following keywords were used: 
 
 • Curcumin 
 • Curcumin analogues and derivatives 
 • Biological Activities of Curcumin 
 • Dyes and Alzheimer´s disease 
 • Synthesis of Curcumin 
 • Curcumin and Alzheimer´s disease 
 
 
According to the broad field of research on Curcumin a great number of papers have 
been published so far. A restricition were done with regard to the significance for the 
present study in the most interesting papers concerning the subject without 
temporally defined limitations towards the publication year. 
The results of the selected papers and conclsions are presented in chapter 4. Results 
and Discussion.  
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4. RESULTS OF THE LITERATURE RESEARCH 
 
4.1. Biological Activities of Curcumin 
 
As current Indian medicine claims the use of turmeric in various medical cases, 
furthermore because of its extensive use in Asian regions for a very long time as 
household remedy, spice and flavouring, and because it has been shown to be very 
non-toxic,1 research has concentrated on evaluating the biological properties of this 
medicinal used plant, in order to develope new drugs which show less toxicity to 
humans.3 
For the last few decades extensive work has been done to establish the biological 
activities and pharmacological actions of turmeric and its extracts. Curcumin 
(diferuloylmethane), the main yellow component of turmeric, has been shown to have 
a wide spectrum of biological actions. These include its antioxidant, anti-
inflammatory, anticarcinogenic, antimutagenic, anticoagulant, antifertility, antidiabetic, 
antibacterial, antifungal, antiprotozoal, antiviral, antifibrotic, antivenom, antiulcer, 
hypotensive and hypocholesteremic activities.74-137 
 
 
4.1.1. Antioxidant Effect 
 
The antioxidant activity of Curcumin was reported  as early as 1975. The compound 
has shown to be a more potent antioxidant than α-tocopherol and acts as a 
scavenger of oxygen free radicals. Curcumin and its three derivatives 
(demethoxycurcumin, bisdemethoxycurcumin and diacetylcurcumin) provide a 
protection of haemoglobin against oxidation at a concentration as low as 0.08mM in 
vitro, whereby diacetylcurcumin possesses the lowest inhibitory activity.74-76 
Curcumin can significantly inhibit the generation of reactive oxygen species (ROS) 
like superoxide anions, H2O2 and nitrite radical generation by activated 
macrophages, which play an important role in inflammation, and it also lowers the 
production of ROS in vivo.2,77 Its derivatives, demethoxycurcumin and 
bisdemethoxycurcumin also have antioxidant effect.78 Curcumin exerts powerful 
inhibitory effect against  
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H2O2-induced damage in human keratinocytes and fibroblasts and in NG 108-15 
cells.79, 80 It was shown to reduce oxidized proteins in amyloid pathology in 
Alzheimertransgenic mice81 and possesses the potency to inhibit lipid peroxidation, 
which plays a main role in the inflammation of heart diseases and in cancer, in rat 
liver microsomes, erythrocyte membranes and brain homogenates.82 This property is 
developed by maintaining the activities of antioxidant enzymes like superoxide 
dismutase, catalase and glutathione peroxidase, which play an important role in the 
regulation of lipid peroxidation at higher levels.83 Since ROS have been implicated in 
the development of various pathological conditions, Curcumin has the potential to 
control these diseases through its potent antioxidant activity.84 
Contradictory to the above-mentioned antioxidant effect, Curcumin has pro-oxidant 
activity. Kelly et al.85 reported that Curcumin not only failed to prevent single-strand 
DNA breaks by H2O2, but also caused DNA damage. As this damage was prevented 
by antioxidant α-tocopherol, the pro-oxidant role of Curcumin has been proved. The 
pro-oxidant activity appears to be mediated through generation of phenoxyl radical of 
Curcumin by peroxidase–H2O2 system, which co-oxidizes cellular glutathione or 
NADH, accompanied by O2 uptake to form ROS.
86 However, the antioxidant 
mechanism of Curcumin is attributed to its unique conjugated structure, which 
includes two methoxylated phenols and an enol form of β-diketone.87, 88 The structure 
shows typical radical-trapping ability as a chain-breaking antioxidant, depending 
upon reaction conditions.89 
 
 
 
4.1.2. Anti-inflammatory Activity 
 
A great number of papers exist relating the activity of compounds extracted from C. 
longa L. being potent inhibitors of inflammation. These substances can be classified 
as curcuminoids, analogues of diarylheptanoids. Anti-inflammatory activity can be 
studied in two different models. In the chronic models (cotton pellet and granuloma 
pouch) where the inflammation and granuloms are developing during a period of 
time, indicating the proliferative phase of inflammation, and the acute model, where 
acute effects of anti-inflammatory agents can be studied, testing their inhibitory action 
on the development of rat paw edema.3 Srimal and Dhawn have examined  
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pharmacological actions of Curcumin90 and they reported that the compound was 
effective in acute as well as chonic models of inflammation. The potency was shown 
as approximately equal to phenylbutazone in the acute model, but it is only half 
active in the chronic experiments. Namely it was observed to be less toxic than the 
reference drug (no mortality up to a dose of 2g kg -1). Curcumin was shown to be 
effective against carrageenin-induced rat paw edema and cotton pellet granuloma 
models of inflammation in rats.91 The natural analogues of Curcumin, [feruloyl-(4-
hydroxycinnamoyl)-methane] (FHM) and [bis-(4-hydroxycinnamoyl)- methane] 
(BHM), are also potent anti-inflammatory agents1,92 as well as the volatile oil,93 the 
petroleum ether, alcohol and water extracts of C. longa show antiinflammatory 
effects.94 Recently it has been reported that Curcumin stimulates stress-induced 
expression of stress proteins and may act in a way similar to indomethacin and 
salicylate.95 Curcumin offers anti-inflammatory effect through inhibition of NFkB 
activation96 and has also been shown to reduce the TNF-α-induced expression of the 
tissue factor gene in bovine aortic-endothelial cells by repressing activation of both 
AP-1 and NFkB.97 The antiinflammatory role of Curcumin is also mediated through 
downregulation of cyclooxygenase-2 and inducible nitric oxide synthetase through 
suppression of NFkB activation.98 Curcumin enhances wound-healing in diabetic rats 
and mice99 and in H2O2-induced damage in human keratinocytes and fibroblasts.
79
 It 
was also demonstrated as an inhibitor of leucotriene formation in rat peritoneal 
polymorphonuclear neutrophils (PMNL), with an EC50 of 27 x 10
-7 M, in contrast, the 
hydrocortisone did not show any effect.100 
 
 
 
4.1.3. Anticarcinogenic Effect – Induction of Apoptosis 
 
Curcumin acts as a potent anticarcinogenic compound. Among various mechanisms, 
induction of apoptosis plays an important role in its anticarcinogenic effect. ICurcumin 
induces apoptosis and inhibits cell-cycle progression, both of which are instrumental 
in preventing cancerous cell growth in rat aortic smooth muscle cells.101 The 
antiproliferative effect is mediated partly through inhibition of protein tyrosine kinase 
and c-myc mRNA expression and the apoptotic effect may partly be mediated 
through inhibition of protein tyrosine kinase, protein kinase C, c-myc mRNA 
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expression and bcl-2 mRNA expression.101 Curcumin induces apoptotic cell death by 
DNA-damage in human cancer cell lines, TK-10, MCF-7 and UACC-62 by acting as 
topoisomerase II poison.102 It causes rapid decrease in mitochondrial membrane 
potential and release of cytochrome c to activate caspase 9 and caspase 3 for 
apoptotic cell death.103 Recently, an interesting observation was made regarding 
curcumin-induced apoptosis in human colon cancer cell and role of heat shock 
proteins (hsp) thereon. In that study, SW480 cells were transfected with hsp 70 cDNA 
in either the sense or antisense orientation and stable clones were selected and 
tested for their sensitivity to Curcumin. Curcumin was found to be ineffective to cause 
apoptosis in cells having hsp 70, while cells harbouring antisense hsp 70 were highly 
sensitive to apoptosis by Curcumin as measured by nuclear condensation, 
mitochondrial transmembrane potential, release of cytochrome c, activation of 
caspase 3 and caspase 9 and other parameters for apoptosis.104 Expression of 
glutathione S-transferase P1-1 (GSTP1-1) is correlated to carcinogenesis and 
Curcumin has been shown to induce apoptosis in K-562 leukaemia cells by inhibiting 
the expression of GSTP1-1 at transcription level.105 The mechanism of Curcumin-
induced apoptosis has also been studied in Caki cells, where Curcumin causes 
apoptosis through downregulation of Bcl-XL and IAP, release of cytochrome c and 
inhibition of Akt, which are markedly blocked by N-acetylcysteine, indicating a role of 
ROS in curcumin-induced cell death.106 In LNCaP prostrate cancer cells Curcumin 
induces apoptosis by enhancing tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL).107 The combined treatment of the cell with Curcumin and TRAIL 
induces DNA fragmentation, cleavage of procaspase 3, 8 and 9, truncation of Bid 
and release of cytochrome c from mitochondria, indicating involvement of both 
external receptor- mediated and internal chemical-induced apoptosis in these cells.107 
In colorectal carcinoma cell line, Curcumin delays apoptosis along with the arrest of 
cell cycle at G1 phase. Curcumin also reduces P53 gene expression, which is 
accompanied with the induction of HSP-70 gene through initial depletion of 
intracellular Ca2+.108 Curcumin also produces nonselective inhibition of proliferation in 
several leukaemia, nontransformed haematopoietic progenitor cells and fibroblast cell 
lines.109 That Curcumin induces apoptosis and large-scale DNA fragmentation has 
also been observed in Vγ9Vδ2+ T cells through inhibition of isopentenyl 
pyrophosphate-induced NFkB activation, proliferation and chemokine production.110 
Curcumin induces apoptosis in human leukaemia HL-60 cells, which is blocked by  
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some antioxidants.111 Curcumin suppresses human breast carcinoma through 
multiple pathways and downregulates matrix metalloproteinase (MMP)-2 and 
upregulates tissue inhibitor of metalloproteinase (TIMP)-1, two common effector 
molecules involved in cell invasion.112 However, Curcumin affects different cell lines 
differently. Whereas leukaemia, breast, colon, hepatocellular and ovarian carcinoma 
cells undergo apoptosis in the presence of Curcumin, lung, prostate, kidney, cervix 
and CNS malignancies and melanoma cells show resistance to cytotoxic effect of 
Curcumin.113 Curcumin also suppresses tumor growth through various pathways. 
Nitric oxide (NO) and its derivatives play a major role in tumour promotion. Curcumin 
inhibits iNOS and COX-2 production by suppression of NFkB activation.85, 91 
Curcumin also increases NO production in NK cells after prolonged treatment, 
culminating in a stronger tumouricidal effect.114 Curcumin also induces apoptosis in 
AK-5 tumour cells through upregulation  of caspase-3.115 Recently, Curcumin has 
been shown to prevent glutathione depletion in Jurkat cells, thus protecting cells from 
caspase-3 activation and oligonucleosomal DNA fragmentation. Curcumin also 
inhibits proliferation of rat thymocytes. These strongly imply that cell growth and cell 
death share a common pathway at some point and that Curcumin affects a common 
step, presumably involving modulation of AP-1 transcription factor.116 
 
 
 
4.1.4. Other Biological Activities 
 
Pro/antimutagenic Activity 
 
Curcumin exerts both pro- and antimutagenic effects. It was shown to reduce the 
number of aberrant cells in cyclophosphamide-induced chromosomal aberration in 
Wistar rats.117 Turmeric also prevents mutation in urethane (a powerful mutagen) 
models.118  
 
Anticoagulant Activity 
 
Curcumin shows anticoagulant activity by inhibiting collagen and adrenaline-induced 
platelet aggregation in vitro as well as in vivo in rat thoracic aorta.119  
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Antifertility Activity 
 
Petroleum ether and aqueous extracts of turmeric rhizomes show 100% antifertility 
effect in rats when fed orally.120 Implantation is completely inhibited by these 
extracts.121 Curcumin inhibits 5α-reductase, which converts testosterone to 5α-
dihydrotestosterone, thereby inhibiting the growth of flank organs in hamster.122 
Curcumin also inhibits human sperm motility and has the potential for the 
development of a novel intravaginal contraceptive.123  
 
 
Antidiabetic Effect 
 
Curcumin prevents galactose-induced cataract formation at very low doses.124 Both 
turmeric and Curcumin decrease blood sugar level in alloxan-induced diabetes in    
rat.125 Curcumin also decreases advanced glycation and products-induced 
complications in diabetes mellitus.126  
 
 
Antibacterial Activity 
 
Both Curcumin and the oil fraction suppress growth of several bacteria like 
Streptococcus, Staphylococcus, Lactobacillus, etc. The aqueous extract of turmeric 
rhizomes has antibacterial effects.127 Curcumin also prevents growth of Helicobacter 
pylori CagA+ strains in vitro.128 
 
 
Antifungal Effect 
 
Ether and chloroform extracts and oil of C. longa have antifungal effects.129 Crude 
ethanol extract also possesses antifungal activity.130 Turmeric oil is also active 
against Aspergillus flavus, A. parasiticus, Fusarium moniliforme and Penicillium 
digitatum.131  
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Antiprotozoan Activity 
 
The ethanol extract of the rhizomes has anti-Entamoeba histolytica activity. Curcumin 
exhibits anti-Leishmania activity in vitro and several synthetic derivatives of Curcumin 
have anti-L. amazonensis effect.132 Anti-Plasmodium falciparum and anti-L. major 
effects of Curcumin have also been reported.133  
 
 
Antiviral Effect 
 
Curcumin has been shown to have antiviral activity.3 It acts as an efficient inhibitor of 
Epstein-Barr virus (EBV) key activator Bam H fragment z left frame 1 (BZLF1) protein 
transcription in Raji DR-LUC cells. EBV inducers such as 12-O-tetradecanoylphorbol-
13-acetate, sodium butyrate and transforming growth factor-beta increase the level of 
BZLF1 m-RNA in these cells, which is effectively blocked by Curcumin.134 Most 
importantly, Curcumin also shows anti-HIV (human immunodeficiency virus) activity 
by inhibiting the HIV-1 integrase needed for viral replication.135 It also inhibits UV 
lightinduced HIV gene expression.136 Thus Curcumin and its analogues may have the 
potential for novel drug development against HIV. 
 
 
Antifibrotic Effect 
 
Curcumin suppresses bleomycin-induced pulmonary fibrosis in rats. Oral 
administration of Curcumin at 300 mg/kg dose inhibits bleomycin-induced increase in 
total cell counts and biomarkers of inflammatory responses. It also suppresses 
bleomycin-induced alveolar macrophage-production of TNF-a, superoxide and nitric 
oxide. Thus Curcumin acts as a potent antiinflammatory and antifibrotic agent.137 
 
Antivenom Effect 
 
Ar-turmerone, isolated from C. longa, neutralizes both haemorrhagic activity of 
Bothrops venom and 70% lethal effect of Crotalus venom in mice.3 It acts as an 
enzymatic inhibitor of venom enzymes with proteolytic activities. 
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4.2. Chemistry of Curcumin 
 
4.2.1. Chemical Structure  
 
Curcumin, 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one 
(diferuloylmethane) is a secondary metabolite and as mentioned the main yellow 
compound of Curcuma longa rhizomes and exhibits numerous biological 
activities.74-137 In the rhizome it is present together with 5-hydroxy-1-(4-hydroxy-3-
methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one (demethoxycurcumin), 
and 5-hydroxy-1,7-bis(4-hydroxyphenyl)hepta-1,4,6-trien-3-one (bisdemethoxy- 
curcumin) (Fig.14).138  
  
HO OH
O OH
R1 R2  R1=R2=  OCH3     Curcumin 
       R1=  OCH3,  R2=  H    Demethoxycurcumin 
       R1=R2=  H  Bisdemethoxycurcumin 
 
 
Fig. 14  Chemical structure of Curcumin, demethoxycurcumin and bisdemethoxycurcumin.
 
 
Curcumin was first isolated in 1870 and its chemical structure was determined in 
1910, which was subsequently confirmed by synthesis.139 Curcumin itself has a 
unique conjugated structure including two methoxylated phenols, exists in equilibrium 
between the diketo and keto-enol forms, whereby the keto-enol form is strongly 
favored by intramolecular H-bonding140 (Fig. 15) and Curcumin shows potent 
antioxidant activity by its radical chainbreaking ability.141 
 
 
H3CO
HO
OCH3
OH
O O
H3CO
HO
OCH3
OH
O O
H
Curcumin  
 
 
Fig. 15  Diketo and keto–enol form of Curcumin.
141
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The major constituent, Curcumin (diferuloylmethane), is in the most important fraction 
of C. longa L.. It melts at 176-177°C and forms red-brown salts with alkalis. Curcumin 
is insoluble in water and ether and soluble in ethanol, alkalis, ketone, acetic acid and 
chloroform. In the molecule of Curcumin the main chain is aliphatic, unsaturated and 
the aryl group can be substituted or not. 3 
 
 
 
4.2.2. Synthesis of Curcumin 
 
Vogel and Pelletier have been the first who tried to isolate Curcumin as a dye in  
1815,142 but Curcumin was obtained in a crystalline condition not before 1870 by 
synthesis of two independent from each other working scientists named Daube and 
Iwanof-Gajewsky.143 Their estimation differed in respect of the structural composition 
of Curcumin. Daube suggested that Curcumin has a structural formula of C10H10O3 
whereby Iwanof-Gajewsky claimed an easier formula of C4H4O for Curcumin. 
Discomposure arose with another suggested formula by Jackson and Mencke in 
1884 who suggested for Curcumin a formula of C14H14O4.
144 This formula was shown 
to be wrong by Ciamician and Silber145 who hereupon proposed a formula of 
C21H20O6, which was proved to be true by Milobedzka, Kostanecki and Lampe in 
1910.146 Through several evaluations they showed the ferulic acid to be a part of 
Curcumin and therefore they proposed for Curcumin the structural formula of a 
diferoloylmethane as shown in Fig. 15. To confirm the formula to be the right one 
Lampe and Milobedzka started to synthesize Curcumin in 1913 and first tried to build 
dicinnamoylmethane (Fig. 16) as they thought that its the percursor of Curcumin.147 
  
 
 
O O
 Dicinnamoylmethane  
 
 
 
Fig. 16  Structure of dicinnamoylmethane.
147
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The worked out synthetisizing method was shown to be correct, because following 
this mechanism it was also possible to synthetisize diferuloylmethane which 
corresponds in its physical and chemical properties exactly with the natural dye 
Curcumin. The pathway of Lampe et al. shown in scheme 2148 includes 5 steps and 
starts with the reaction of the ethyl acetate with carbomethoxy-feruloylchloride in 
basic conditions to achieve the product of the condensation. Following saponification 
and decarboxylation gave the corresponding carboxymethoxy-diferuloylacetone 
derivative. Refluxing product with acetic acid dil. afforded dicarbomethoxy-
diferuloylmethan. Milobedzka and coworkers compared this structure with the natural 
dicarbomethoxy-curcumin showing complete identity. 
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Scheme 2  First pathway of Curcumin synthesis.
148
 
 
Furthermore as the carbomethoxygroups were eliminated and Curcumin was 
obtained, the pathway was again shown to be the right one.148 
Another work was developed by Ghosh in 1919 in order to prove the structure of 
Curcumin through demonstrating the presence of the -CO-CH2-CO- group. 
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Through several evaluations Gosh and coworkers additionally discovered that 
dicarboethoxycurcumin could be converted into dicarbethoxyisocurcumin very easily. 
The authors showed Curcumin and Isocurcumin to be two geometric isomers.149  
A new method to synthesize Curcumin was proposed by Pabon in 1964150 in  
consideration of the work of Pavoli et al.,143, 144 who prepared Curcumin by heating 
vanillin, acetylacetone and boric anhydride (2:1:2) over a free flame for 30 min. and 
claimed a yield of 10% in this one step procedure as shown in scheme 2. Thus the 
method yielded in practice unsatisfying 1,5% of the product scientists proposed 
different variations of the reaction. 
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Scheme 3  Curcumin synthesis proposed by Pavolini et al. 
143, 144 
 
The low yield was not unexpected due to the high temperatures in this reaction, 
which on the other hand were necessary to get any reaction at all. Pabon and 
coworkers suggested that the low yield is caused by the fact that the vanillin 
condenses with the less reactive methyl groups of acetylacetone and in their opinion 
this behavior must be ascribed to the properties of the acetylacetone/boric anhydride 
complex which was not mentioned by Pavolini and probably has the suggested 
structure shown in Fig 17.151, 152 
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Fig. 17  Acetylacetone/boric anhydride complex.
151
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The structure occuring in the reaction was proposed to be as shown in Fig. 18  and 
this complex is decomposed by diluted acids and bases.153 
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Fig. 18  Curcumin-acetylacetone/boric anhydride complex.
153
 
 
Hence the new idea of Pabon et al.150 was to use diluted acids because Curcumin 
itself is unstable towards alkali. Keeping these proposals in consideration and 
because they observed that the condensation of vanillin and acetylacetone in the 
presence of boric anhydride took place at 150°C, if minor amounts of butanol and 
piperidine were also present, they thought that boric esters and bases like piperidine 
might be used with success for this type of condensation. Their experiment with 
tributyl borate, piperidine and the reaction product of acetylacetone and boric 
anhydride prompted them to study all factors involved systematically. They found that 
the best temperature range for this condensation was 80 -110°C and higher yields 
could be obtained by using a solvent. The results are shown in table 2.150 
 
 
Trialkyl  borate     Yield of Curcumin (%) 
Trimethyl borate      63 
Triethyl borate      71 
Tripropyl borate      72 
Tri-isopropyl borate      80 
Tri-n-butyl borate      73 
Tri(2-butyl) borate      78 
Tri-isobutyl borate      69 
Tri-tert.butyl borate      58 
Tripentyl borate      59 
Tri(2-methylbutyl) borate     66 
Trioctyl borate      57 
Trioctadecyl borate      +/-5 
 
 
 
Table 2  Influence of the nature of the trialkyl borate on condensation at room temperature of 0.4 mole of vanillin with the 
reaction product from 0.2 mole acetylacetone and 0.14 mole of boric anhydride in 200 ml of ethyl acetate, adding 0.8 mole 
trialkyl borate and 4 ml butylamine.
150
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The improvement of this synthesis (shown in scheme 4) by using tributyl borate and 
piperidin as catalysts and the freshly prepared complex of acetylacetone and boric 
anhydride led to a significant increase of the yields. Some Curcumin derivatives, 
using vanilin (or benzyldehyde derivatives), tributyl borate, ethyl acetate, the complex 
of acetylacetone and boric anhydride have been synthesized using this method.139 
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Scheme 4  Synthesis of Curcumin as proposed by Pabon.
139
 
 
In a work of Roughly and Whiting154 investigating the biosynthesis of natural 
diarylheptanoids with particular reference to Curcumin it was shown that the 
biosynthesis of Curcumin involves two cinnamate units which are coupled to a central 
carbon provided by malonate and therefore showed a new way of achieving 
Curcumin (scheme 5). 
If biosynthesis does follow the steps shown in scheme 5 some activity might be 
expected in the cinnamate-derived units, incorporated either via eventual 
participation of acetate, through pyruvate, in phenyl-alanine metabolism, or through 
degradation to carbon dioxide. It would be surprising if such processes were more 
effective in acetate and malonate utilisation than the direct incorporation into the 
central methylene, unless some form of compartmentalisation happens. 
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Scheme 5  Curcumin biosynthesis involving two cinnamate units.
154
  
 
 
A possible alternative route for Curcumin formation was suggested as shown in 
scheme 6. 154 
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Scheme 6  Alternative pathway of curcumin biosynthesis.
154
 
 
 
The route involved a cinnamate starter, extended by five acetate (malonate) units, 
the cyclization of the chain gives the second aromatic ring (reduction before 
cyclization removes the 6´- and the 10´-hydroxy-function) and the biosynthesis would 
be completed by hydroxylation at C-7´. A lot of variations are possible because 
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of different unknown influences. It was proposed that ferulic and rosmarinic acid are 
acceptable percursors to Curcumin and to date the most used synthesis of Curcumin 
is the synthesis of Curcumin proposed by Pabon (scheme 4 ).139 
 
 
 
4.2.3. SAR of Synthesized Curcumin Analogues 
 
The various properties of Curcumin have attracted much attention and in the years 
after its synthesis several analogues have been obtained through chemical 
modifications on the basic structure of Curcumin in attempt to increase its 
effectiveness and decrease the potential toxic effects. Some of these analogues 
have been reported to possess a higher anti-inflammatory activity than 
phenylbutazone.132 
On the basis of the biological activity and the easy synthetical approach, Curcumin 
was used as a lead compound to design Curcumin derivatives with the purpose of 
examining their anti-inflammatory activity.139 Therefore, the anti-inflammatory activity 
of Curcumin, diacetylcurcumin (DAC), triethylcurcumin (TEC), tetrahydrocurcumin 
(THC) and phenylbutazone (PB) has been studied (Fig.19). 
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Fig.19  The substances tested on anti-inflammatory activity.
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These analogues showed anti-inflammatory (protective) as well as inflammation-
increasing (irritant) effects. The highest potency showed tetrahydrocurcumin. 
Altogether 16 Curcumin analogues were prepared and some physico-chemical 
properties could be summarized as follows.139 
The compound without substituents at the phenyl rings shows little inhibition in anti-
inflammatory assays, whereas substitution at the 4-position of each phenyl ring by 
hydroxy, methoxy or methyl significantly increases the activity over the unsubstituted 
derivatives. Introduction of a chloro atom in the 4-position does not increase the anti-
inflammatory effect, which may suggest that an electron-donating substituent in the 
para position is favorable for activity. Among the mono-substituted compounds the 
hydroxy derivative showed the highest activity (ED50= 73mg/kg). Moreover, addition 
of a methoxy group in the 3- or 2- position instead of the 4-position causes a 
significant decrease in activity, therefore mono-substitution at ortho and meta position 
is not sufficient for activity. Furthermore, the introduction of methyl groups in the 3- 
and 5-position affords the most active compound (ED50= 13mg/kg) in the series of 
methoxylated and alkylated 4-hydroxy derivatives. Compared to this they found the 
opposite effect by substituting the 3- or 5- position of the 4-methoxy analogue, here 
the activity was increased with a methoxy group, and the introduction of benzoyloxy 
groups in the 3- and 4-position, maybe because of sterical reasons, caused a 
complete loss of activity.139  
Altogether it was shown that the olefinic double bonds, the 4-hydroxyl groups and the 
presence of one 3-methoxy group are important for the anti-inflammatory activity, and 
besides this, the substituents at meta positions are important for activity as well. Thus 
the bigger substituents (tert-butyl) lead to inactivity, analogues without 4-
hydroxygroups have low or no activity and the compound with 3-methyl groups 
shows the highest activity in the inflammatory tests based on the inhibition of the 
carageenin-induced swelling of rat paw.139 
 
In another approach Curcumin analogues were assayed in vitro against L. 
amazonensis promastigotes with using pentamidine isethionate as reference drug.132 
Several modified analogues were tested. Comparing the results in table 3 it can be 
observed that the compounds 1,7-bis-(3,4-dimethoxyphenyl)-1,6-heptadien-3,5-dione  
and 1,7-bis-(4-proparagyl-3-methoxyphenyl)-1,6-heptadiene-5,5-dione (Fig. 20) show  
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the highest activity against L. amazonensis, followed by the derivatives shown in 
table 3. It was obsreved that the substitution of the hydroxylgroup in 
hydrazinocurcumin with a propargylgroup brings an enhancement of nearly 10 times 
in the leishmanicidal activity whereas the absence of para propargyl group decreases 
the effect.132  
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Fig. 20  Most potent derivatives in leishmanicidal activity.
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Compound                 LD50 (µg/ml)
3 
 
1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one   9.00 ±2 
1,7-bis-(4-hydroxy-3-methoxyphenyl)-heptane -3,5-dione   23.10 ±2 
1,7-bis-(4-hydroxy-3-methoxyphenyl)-heptane-3,5-diol    51.23 ±3 
1,7-bis-(3,4-dimethoxyphenyl)-1,6-heptadiene-3,5-dione   2.00 ±5 
1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-diol   39.24 ±4 
1,7-bis-(4-acetoxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione   17.55 ±3 
1,7-bis-(4-acetoxy-3-methoxyphenyl)-heptane-3,5-dione   27.10 ±4 
1,7-bis-(4-propargyl-3-methoxyphenyl)-1,6-heptadiene-3,5-dione   1.24 ±5 
1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-acetonide  14.12 ±2 
1,7-bis-(3,4-dimethoxyphenyl)-1,6-heptadiene-3,5-diol    25.32 ±5 
Pentamidine        0.278        ±0.001 
 
 
 
 
Table 3  Compounds and results of the tested anti leishmanicidal activity.
132  
 
Unfortunately the results did not allow to postulate any correlation between the 
leishmanicidal activity and the chemical structures. Although it was suggested that 
the phenol group is essential in Curcuminoids for good biological effects, and the non 
phenolic compounds 1,7-bis-(3,4-dimethoxyphenyl)-1,6-heptadien-3,5-dione and 1,7-
bis-(4-proparagyl-3-methoxyphenyl)-1,6-heptadiene-5,5-dione were much more 
effective against L. amazonensis. This leads to the suggestion that the leishmanicidal 
activity may be related to other structural features, such as the presence of the β-
dicarbonyl system, the α,β- unsaturated system and the increasing electronic density 
in the aromatic ring.132  
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Shim and coworkers designed several Curcumin analogues in expectation to 
enhance the biological, especially anti-angiogenic, activity. The evaluation of in vitro 
and in vivo assays of these derivatives shows that hydrazinocurcumin (Fig. 21) 
possesses a 30 times higher inhibitor-potency against bovine aortic endothelial cells 
(BAECs) than Curcumin.155 
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Fig. 21 Tested hydrazino- and hydrazinobenzoylcurcuminoids byShim and coworkers.
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Several studies on the SAR of Curcuminoids have revealed that the presence of the 
aromatic moieties is essential for the antioxidant activity. The diketone moiety of 
tetrahydrocurcumin also involves antioxidant mechanism and in addition, phenolic 
hydroxyl or methoxyl groups were modified to enhance the potency of other biological 
activities of Curcumin. Studies suggest that the diketone moiety of Curcumin may be 
essentially involved in its tremendous biological activities. In that work the diketone 
moieties of each Curcumin analogue were replaced with hydrazine derivatives in the 
presence of acetic acid and the highest activity showed hydrazinocurcumin  with an 
IC50 of 0.52 µM. The compounds with bulky benzoic acid moiety also obtain 
enhanced anti-proliferative activity, but in a weaker potency than 
hydrazinocurcumin.155 
In the frame of another investigation devoted to the development of selective 
cytotoxic antitumor agents 32 Curcumin analogues (diarylheptanoides) were 
prepared and their cytotoxic effects were evaluated. In the same work also  
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26 diketo compounds structurally related to Curcumin were designed and a selected 
number of them were tested in a drug resistance reversal assay.156 Among the 32 
diarylheptanoids the hydrogenated (saturation of olefinic bond) as well as the cyclic 
diarylheptanoids (Fig. 22) were inactive, therefore the presence of the conjugated β-
diketone in the cyclic carbon chain appears to play an important role for cytotoxicity in 
this class of compounds. 
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Fig. 22  Tested hydrogenated and cyclic diarylheptanoids.
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The bis-substituted diarylheptanoid compound which is o-fluorinated on each 
benzene ring displays a broad cytotoxicity spectrum but borderline activity. The 
remaining fluorinated diarylheptanoids were inactive (Fig 23). 
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Fig. 23  Tested fluorinated compounds.
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By comparing the cytotoxicity results of the remaining diarylderivatives following 
SARs were established.156 Converting the keto-enol moiety to the correspondending 
pyrazole (Fig. 24) lead to increased cytotoxicity against various cell lines. 
Thus, the ring substituents affected the activity in the pyrazole derivatives.  
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Fig. 24  The convertation of the keto-enol moiety to the pyrazole leads to increased cytotoxicity.
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Demethylation or methylation of Curcumin to form the dihydroxy- and the 
trimethylderivatives (Fig. 25), respectively, increased cytotoxicity against determined 
cells. Therefore, the presence of catechol or 3,4-dimethoxyphenyl substituents 
enhanced the cytotoxic properties.156 
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Fig. 25  Achieved compounds through methylation and demethylation of Curcumin.
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It was concluded that the position and nature of the substituents on the benzene ring 
modulate antitumor activity.156  
Among the 26 1,3-diaryl-1,3-diketone-propane and related analogues (Fig. 26) 
following SARs can be summarized. The β-diketone moiety enhances the cytotoxic 
properties, introduction of tert-butyl group (an electron-donating substituent) on the 
phenyl ring and replacement of the hydrogenatom with fluorine (an electron-
withdrawing substituent) at the para position, respectively, leads to increase 
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cytotoxicity against certain cells. Compared to unsubstituted the β-bromination 
between the keto groups led to enhanced activity but substituition by nitroso-, 
benzoyl-, methyl- and furan moieties at this position abolished activity. 
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Fig. 26  Delineation of synthesized propane analogues.
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The compound which has an α-bromo substituent and 4-nitro and 4-methoxy groups 
on seperate benzene rings (Fig. 27) demonstrated the strongest cytotoxic effects 
against HOS (bone cancer) and 1A9 (breast cancer) cells with ED50 values of 0.97 
and <0.63µg/mL, respectively. 
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Fig. 27  Compound with the strongest cytotoxic effects against HOS and 1A9.
156
 
 
It was confirmed that asymmetrical substitution led to enhanced activity and different 
electronegative aryl substituents (4-nitro, 4-methoxy) to increased activity against 
1A9 and HOS cells. In addition to that, replacing the phenyl groups with thiophenyl 
groups increased cytotoxicity against HOS and A19 cell lines.156 
The efforts towards the design of new Curcumin analogues in another work have 
focused on the truncation of the general structure to either a single enone or dienone 
system.157 All new compounds were prepared according to the same general 
synthetic procedure, the utilization of classic Claisen-Schmidt reaction, or obtained 
commercially. A reasonable approach was to explore compounds with systematic 
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differences in the carbon chain connecting the two aromatic regions and small-
molecule anti-angiogenic analogues of Curcumin are attractive targets. Examination 
of Curcumin suggested that the two aromatic regions might be critical for potential 
ligand-receptor binding, therefore a preliminary pharmacological model devided 
Curcumin in three regions (Fig. 28). Region A required an aromatic ring, region B 
was composed of a symmetrical dienedione linker, and region C also required an  
aromatic ring.157 
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Fig. 28  Schematic demonstration of the differentiation into three regions.
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Based on this simple model, various linkers in region B were prepared or obtained 
commercially and by modifying the linker to an enone or dienone, two new series 
possessing antiangiogenic properties were discovered (Fig. 29).157 
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Fig. 29  Synthesized enone and dienone derivatives with antiangiogenic properties.
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Among the enone compounds it was initially hypothesized, assuming potential 
nucleophilic addition with the enone, that substituents in position 2 and 6 of the 
aromatic ring in Region A might affect inhibition via stereoelectronic effects resulting 
from a conformational change. Adjusting the aromatic rings in Regions A and C and 
substitution of the phenyl ring in Region A with a pyridyl ring yielded the compound  
1-Phenyl-3-pyridin-2-yl-propenone with excellent inhibition. The parent aromatic 
dienone compounds are cyclohexanone and acetone derivatives. As before in the 
enone series, the importance of stereoelectronic effects and the effect of 
conformational changes were explored by altering the aromatic substituents in 
Regions A and C, substitution of both phenyl rings, Region A and C, with pyridyl rings 
yielded 2,6-Bis-pyridin-2-ylmethylene-cyclohexanone which also possessed excellent 
inhibition. 2,6-Bis-(4-hydroxy-3-methoxybenzyl)-cyclohexanone was examined 
because of the similar functional group patterns to Curcumin (3-methoxy 4-hydroxy 
aromatic substitution patterns). The work led to the conclusion that aromatic enone 
and aromatic dienone analogues of Curcumin were excellent antiangiogenic 
compounds, having inhibition patterns equivalent or better than the parent natural 
product.157 
After several studies focusing mainly on changes in the β-diketone structure and aryl 
substitution, the intent of a novel work was to explore mono-carbonyl derivatives and 
diarylpentanoides to see whether they would possess increased anti-cancer and anti-
angiogenic activity.158 Through database searching two compounds were found with 
high similarity to Curcumin (Fig 30), the monoketones 1,5-bis(3,4-dimethoxyphenyl)-
1,4-pentadiene-3-one (BDMPP) and 2,6-bis((3-methoxy-4-hydroxyphenyl)-
methylene)-cyclohexanone (BMHPC). 
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Fig. 30  The through database searching found compounds with high similarity to Curcumin.
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These compounds were tested in a number of in vitro cell viability screens and it was 
evaluated that they possessed a higher activity compared to Curcumin. As a follow 
up, a number of novel mono-ketone lead compounds were synthesized and  
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biologically evaluated as potential anti-cancer and anti-angiogenesis agents. Similar 
studies on mono-ketones were evaluated before but an important distinction between  
the old studies and the new work is the location of the aryl substituents in the ortho-
position. The main object of present investigations is the synthesis and testing of a 
number of symmetrical (scheme 7), but truncated Curcumin analogues in order to 
develop novel, active and selective anti-cancer and anti-angiogenesis agents.158 
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Scheme 7  Synthesis of symmetrical, truncated Curcumin analogues.
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α-β-Unsaturated ketones were produced to allow biological assessments by varying 
the substituents on the aromatic ring and the α-carbons of ketones, respectively. All 
three mono hydroxy groups were explored because of reported increase of activity. 
Further the replacement of the hydroxy groups with methoxy groups or fluorine were 
studied and the annulation of α-carbons allowed examinations of the preferred steric 
environment for this region as well as to study the bioeffects through modifying 
hydrophobicity.158 The tested analogues showed a broad spectrum of activity as well 
as distinctive patterns of selectivity. Among all tested derivatives the ortho fluoro 
substituted piperidone analog (Fig 31) proved to be the most active compound, even 
more active than Curcumin and cisplatin, a DNA crosslinking agent that is commonly 
used in the treatment of a number of different cancers. 
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3,5-bis-(2-fluorbenzylidene)-piperidin-4-one  
 
 
Fig. 31  The ortho fluoro substituted piperidone analogue with the highest activity.
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3,5-bis-(2-fluorbenzylidene)-piperidin-4-one, acetic acid salt was also tested in vivo 
and seems to have potential as a chemotherapeutic agent since it demonstrated 
better activity but lower toxicity than a commonly used drug. Following general 
conclusions could be summarized: 
As previously shown ortho-Substitution on the aromatic rings enhanced the activity of 
the symetrical analogues while substitution in the meta- or para- position led to 
inactive compounds. The symmetrical α-β-unsaturated ketone structure found in the 
novel analogues showed increased in vitro anti-cancer and anti-angiogenesis activity 
compared to the diketone structure of Curcumin. Introduction of heteroatomes in the 
cyclic ketone portion yielded compounds with improved anti-cancer and anti-
angiogenesis activity. Saturation of the olefinic bond of the α-β-unsaturated ketones 
produced an arylethyl alcohol that possessed little anti-cancer and direct anti-
angiogenic activity.158 
In order to search new antitumor agents acting on mitochondrial various analogues of 
Curcumin were synthesized and compared to the well known uncoupler agent 
carbonyl cyanide m-chlorophenylhydrazone (CCCP) and it was presented evidence 
that two of these agents (Fig 32) obtained by chemical substitution of Curcumin are 
able to combine the pro-oxidant PTP (permeability transmittion pore) inducing 
properties of the parent drug Curcumin with potent mitochondrial uncoupling 
properties.159 
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Fig. 32  Synthesized compounds with promising anti-tumor activities.
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The replacement of methoxygroups by fluorine atoms induced three significant 
physico-chemical changes, namely an enhancement of the phenolic acidity, a large 
increase in partition coefficient in n-octanol/water biphasic system, and a large 
increase in ΔlogPNoct-npoe parameter, thus compared to the methoxy derivatives the 
fluorinated derivatives showed higher lipophilicity and higher acidity which suggests 
that the substitution of fluoride increases the concentration of anionic forms in organic 
media such as mitochondrial membranes. The measurement of lipophilicity of the 
anionic form was not possible, but the accumulation of anions in the organic phase 
could be seen qualitatively in partition experiments by changes in organic phase 
coloration. These effects are markedly important for fluorine derivatives at pH around 
pH 7.0 underlining that not only high lipophilicity but also high acidity and high 
complexation power may be responsible for the increase in uncoupler effects of Cu12 
and Cy12. Therefore, these two compounds may represent interesting anti-tumor 
agents.159 
 
Based on previous results of Curcumin potencies it was hypothesized that the rigidity 
of symmetrical aromatic moieties plays an important role to enhance antiangiogenic 
activity. Therefore symmetrical bis-aromatic alkynyl pyridine and thiophene 
derivatives representing the rigid structure of Curcumin (Fig. 32) and bis-aromatic 
alkyl pyridine and thiophene derivatives were synthesized.160 
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Fig. 32  Demonstration of the structural rigidity which is thought to be important for enhanced antiangiogenic activity.
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For the ability to study the relationship between structural rigidity and activity the 
alkynyl compounds were hydrogenated with Pd/C at room temperature in the H2 
atmosphere, respectively (scheme 8). As expected the bis-alkynyl coumpounds, rigid 
mimetic structure of Curcumin, showed more potent growth inhibitory activity than 
Curcumin itself. The bis-alkynyl-pyridine derivatives possess stronger inhibitory 
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activity than the thiophene derivative.14 The watersolubile derivatives of these bis-
alkynyl compounds, which were also obtained through hydrogenation and had more 
flexible alkyl chain, showed similar inhibition activity to Curcumin. The authors found 
that the rigid mimetic structure has a strong anti-angiogenic activity and improved the 
biological activity.160 
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Scheme 8  Synthesized compounds which were achieved through hydrogenation.
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A recent work described the covalent attachment of Curcumin with ligands that 
internalize with cellular invironment of infected cells. They used the aminoacids glycin 
and D-alanin, wich are essential compounds of bacterial cells, and glucose and 
acetic acid being food components and also recognized by cells. Since piperin has 
been proved to enhance bioavailability of drugs they also linked Curcumin with 
piperin to achieve more efficient bioconjugates. The aims were to ease the 
transmembran passage of Curcumin and a decrease of metabolism inside the cell, 
respectively. Furthermore to enhance hydrophobicity and to have a biodegradable 
linkage in the bioconjugate, which could be degraded by the cellular enzymes and 
Curcumin released at the drug target site (pro-drug).161 The conjugates shown in  
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Fig. 33 were synthesized and following results were concluded. Tested in vitro on a 
lot of multiresistant strains of bacteria and funghi the compounds proved to have 
higher hydrophobicity as Curcumin and the antibacterial and antifungal activity is 
significantly increased.15 Thus there is a need to develop novel nonantibiotic drugs to 
overcome antibiotic resistance these compounds are promising targets for further 
investigations.161 
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Fig. 33  Derivatives that were achieved through connection with glycin, D-alanin, glucose, acetic acid and piperin.
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In a novel study of Curcumin analogues as potential COX-1/COX-2 inhibitor pyrazol 
and isoxazol derivatives were designed and showed a higher antioxidant activity than 
trolox and a significantly enhanced COX-1/ COX-2 selectivity.162 In previous literature 
it was fond that Curcumin was investigated for COX inhibitory activity. One pyrazol 
analog of Curcumin was investigated for lipoxygenase inhibitory and the three 
pyrazole derivatives of curcuminoids were synthesized and evaluated for endothelial 
cell proliferation and cytotoxic activity.155, 156 The curcuminoids Curcumin, 
demethoxycurcumin and bisdemethoxycurcumin were isolated and the pyrazole and 
isoxazole analoges were prepared by treating the CH2Cl2 extract as shown in 
scheme 9.162  
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Scheme 9  Synthesized pyrazole and isoxazole derivatives with antioxidant and COX1/COX2 selectivity.
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Concordantly to previous studies the o-methoxyphenolic moiety of the pyrazole and 
isoxazole derivatives showed to be essential for antioxidant property. 
Hydrazinocurcumin was found to be more potent than Curcumin 155 and the isoxazol 
derivative shown in scheme 8 was equipotent. Compared to trolox compounds 
Curcumin, hydrazinocurcumin, the isooxazole derivative showed higher antioxidant 
activity and among them hydrazinocurcumin showed the highest, most probably 
because of the presence of pyrazole NH.162 In COX catalyzed prostaglandin 
biosynthesis assay in vitro COX-1/COX-2 inhibitory activity was tested and 
hydrazinocurcumin and the isooxazole derivative demonstrated better COX-2 
inhibitory activity in comparison to Curcumin. Since these analogues exhibited good 
COX inhibitory and antioxidant activities they were investigated for in vivo anti-
inflammatory activity assay and hydrazinocurcumin showed the highest activity as 
well. Therefore molecular docking studies were performed and these further 
supported the strong inhibitory activity of hydrazinocurcumin compared to the 
others.162 SAR studies revealed that replacement of the β-diketo fragment of 
Curcumin by a pyrazole ring significantly enhances COX-1/COX-2 selectivity. The 
mixed antioxidant and COX inhibitory properties may provide superior anti-
inflammatory activity. Thus, the investigation of the real antioxidant activity, the good 
radical scavenging and the better understanding for the ligands/enzyme interactions 
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in detail through molecular docking studies could lead to novel potent inhibitors in 
future. 
 
Because of the possibility to prepare derivatives of Curcumin with feruloyl acid, a 
work has to be considered where 14 feruloyl-myo-inositol derivatives were prepared 
and the relationship between their stereostructure and inhibitory activity towards the 
12-O-tetradecanoylphorbol-13-acetate (TPA)-induced superoxide (O2
-) generation 
and their supressive effect on the TPA-induced Epstein-Barr Virus (EBV), 
respectively, was evaluated.163 Out of the three structural groups, monoferuloyl-, 
bisferuloyl-, and trisferuloyl-myo-inositol three derivatives showed high biological 
activity (Fig. 34). It was substantiated that the derivative 3-(4-Acetoxy-3-methoxy-
phenyl)-acrylic acid 2,3,4,5-tetraacetoxy-6-(3-phenyl-acryloyoxy)-phenylester in 
which two feroyl moieties are introduced to the hydroxylgroups bond to the 1,2-vicinal 
carbons in myo-inositol exhibit a high supressive activity towards the O2
- generation. 
This observation suggests that the inhibitory effect of bisferuloyl-myo-inositol 
derivatives depends on if the phenolic and inositol hydroxyl groups are protected by 
acetyl group or not, hydrophobicity of the molecules and stereostructure of the 
molecules.163 
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Fig. 34  Synthesized bisferuloyl and trisferuloy derivatives.
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Further they summarized that stereostructures in which two feruloyl moieties were 
introduced into equatorial hydroxyl groups bonded to the 3 and 6 carbons in  
myo-inositol demonstrated low activities and the structure which had two feroyl 
moieties introduced into the equatorial hydroxyl groups bonded to the vicinal 1 and 6 
carbons in myo-inositol and the hydroxyl group of the system was not protected 
showed high supressive activity on the O2
- generation. The trisferuloylderivative 
showed a distinct inhibitory activity toward the TPA- induced EBV activation. It was 
suggested that the suppressive activity of this compound may be attributed to its 
special molecular structure in which ferulic acid are facing each other by the use of a 
myo-inositol 1,3,5-orthoformate skeleton.163 
Thus the results showed that in the bisferuloyl group protection of the hydroxy group 
enhances activity, however in the group of trisferuloylderivatives an increase of 
activity was achieved with protection of the hydroxy group. Concluding, it can be said, 
that the inhibitory potencies of these derivatives may depend on the stereostructure 
of the molecules rather than on the hydrophobicity of molecules.163 
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4.3. Curcumin and its Properties in Aβ-Induced 
 Cytotoxicity 
   
Since it is known that in neurodegenerative diseases including Alzheimer´s disease 
besides other aspects also both oxidative damage and inflammation have been 
implicated,11 and because of strong evidence that antioxidants can protect from in 
vitro β-amyloid toxicity and resulting oxidative damage,164 a clinical trial testing the 
ability of high dose of the anti-oxidant α-tocopherol to slow AD progression was 
carried out.165 The modest success of this trial in slowing the decline in activities of 
daily living has stimulated interest in antioxidant approaches. It remained unclear to 
what extent the tested vitamin E in form of α-tocopherol affected the oxidative 
damage, neuronal dysfunction, synapse loss and other pathogenic events, but it was 
shown, that one natural alternative antioxidant to vitamin E is the polyphenolic 
antioxidant Curcumin, found in turmeric.11  
Knowing that the yellow curry spice Curcumin shows antioxidant and anti-
inflammatory activities,1 and that age-adjusted Alzheimer´s prevalence in India, where  
Curcumin is used almost every day, is roughly one quarter of the rates in the United 
States in those aged 80 years or older166 research started to concentrate on the 
properties of Curcumin. Curcumin was reported to be several times more potent than 
vitamin E as a free radical scavenger81 and effectiv against nitric oxid based 
radicals.167 Furthermore oral administration of Curcumin has been shown to be 
centrally neuroprotective.168 
Therefore, considering that Curcumin with its antioxidant and anti-inflammatory 
properties protects against neurotoxic and genotoxic agents, it was hypothesized that 
dietary Curcumin acting as combined antioxidant and NSAID agent might also have 
significant preventive activity against Aβ-induced neurotoxicity and cognitive 
deficits.11 In an assay where 22 month Sprague-Dawley (SD) rats were used to 
compare the effects of the conventional NSAID, ibuprofen, and Curcumin for their 
ability to protect against amyloid β-protein (Aβ)-induced damage. It was shown that 
Curcumin besides other good influences on oxidative damages markedly reduced 
total Aβ plaque numbers compared to control diet fed animals and its potencies were 
shown to be greater than ibuprofen.11 
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Furthermore Curcumin was tested for its ability to inhibit the combined inflammatory 
and oxidative damage that occurs as a response to amyloid in the transgenic mouse 
model APPs. This model carries a human familial AD gene (amyloid percursor 
protein with the “Swedish” double mutation)169 and shows age-related neuritic plaque 
pathology, an inflammatory response, oxidative damage and age-related memory 
deficits linked to defective long-term potentiation (LTP),170 representing the factors 
that are implicated in AD. It was established that Curcumin in a dose dependent 
manner is able to suppress the inflammatory cytokine IL-1β and the astrocytic 
inflammatory marker GFAP, to reduce oxidative damage and it decreased overall 
insoluble amyloid, soluble amyloid and plaque burden.81 Recognizing that these Aβ-
lowering effects were not mediated by reductions in APP expression, because there 
was found no decrease in APP production, the mechanisms underlying these 
Curcumin treatment effects are thought to be multifunctional as shown in 
scheme 10.81 
It was suggested that Curcumin blocks AD pathogenesis at multiple sites. Curcumin 
can act as a scavenger of ROS, including NO and peroxynitrite generated by reactive 
glia and hydroxyl radicals generated by neurons as a result of direct Aβ toxicity. 
Ibuprofen (NSAID action at site 1) can inhibit microglial activation and cytokine 
production, but was not sufficient to reduce oxidative damage. Curcumin also 
limits damage by inhibiting NFkB (nuclear factor kB) induced iNOS (inducible nitric  
oxide synapse), cyclooxygenase 2, and inflammatory cytokine production by reactive 
glia. 
 
 
Scheme 10  Multifunctional mechanism of Curcumin in AD.
171
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By blocking NFkB and reducing interleukines IL-1β, IL-6, and Apolipoprotein ApoE, 
Curcumin also should reduce proamyloidogenic factors (ApoE, α1ACT (alpha-1-
antichymotrypsin)). Furthermore Curcumin can lower plasma and tissue cholesterol, 
potentially lowering Aβ-production as well as Lipoxygenase (LOX), cyclooxygenase-2 
(COX-2), scavenger receptors (SCR) and Fc Ig receptors (Fc).171-174 Besides all 
these findings the direct effects of Curcumin on the formation and destabilization of 
Aβ-fibrillogenesis remained unclear.  
 
Consequently other investigations concentrated on examining the effects of 
Curcumin and its analogue, rosmarinic acid (RA), on the formation and extension of 
Aβ(1-40)fibrils and Aβ(1-42)fibrils, as well as their activity to destabilize Aβ-fibrils at  
pH 7.5 at 37 °C in vitro. It was shown that Curcumin and rosmarinic acid dose-
dependently inhibit β-amyloid fibrils (fAβ) formation from fresh Aβ, and destabilize 
preformed fAβ in vitro.12 The two analogues were compared to nordihydroguaiaretic 
acid (NDGA) which possess the ability of inhibiting fAβ formation from Aβ to fAβ 
extension in vitro and showed a similar anti-amyloidogenic activity as Cur and RA  
because of structural similarity (Fig. 35).175 
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Fig. 35  Structure of Curcumin (Cur), nordihydroguaiaretic acid (NDGA) and rosmarinic acid (RA).
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All of these molecules own two 3,4-dihydroxyphenyl rings (NDGA, RA) or 3,4-
methoxyhydroxyphenyl rings (Cur) symmetrically bound by a short carbohydrate 
chain and this compact and symmetric structure might be suitable for specifically  
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binding to free Aβ and subsequently inhibiting polymerization of Aβ into fAβ.14 Cur, 
RA and NDGA were proposed to have different mechanism compared to ApoE, 
which was suggested to inhibit through formation of complexes with Aβs and thus 
eliminating free Aβs from the reaction mixture.175 Cur is thought to be able to bind to 
the end of extending fibril-Aβ(1-40) and increase the rate of depolymerization by 
destabilizing the conformation of Aβ(1-40) that just has been incorporated into the 
fibrils end.14 Further efforts to clarify the mechanisms by which Cur as well as RA 
inhibit formtion in vitro are essential. 
 
In another assay considering the interaction of soluble Aβ(1-40) or fibrillar Aβ(1-42) 
caused activation of nuclear transcript factor, early growth response-1 (Egr-1), which 
resulted in increased expression of cytokines (TNF-α and IL-1β) and chemokines  
(MIP-1β, MCP-1 and IL-8) in monocytes176 and because Curcumin was shown to 
inhibit phorbol-ester (4β-phorbol 12-myristate 13-acetate; PMA) – induced activation 
of Egr-1, AP-1 and NF-kB in endothelial cells.177, 178 Egr-1 was explored as a 
molecular target for preventing inflammation utilizing a small organic molecule like  
Curcumin.26 It was found that Curcumin inhibited Aβ-induced expression of Egr-1 
protein and Egr-1 DNA-binding activity in THP-1 monocytic model cells that results 
concomitantly of the attenuation of the Aβ(1-40)- mediated gene expression of TNF-
α, IL-1β, IL-8 and MCP-1, indicating either a direct or causal effect. This study thus 
provided one mechanism, among several multifactorial effects, by which Curcumin 
abrogates amyloid peptide-induced inflammation. Furthermore it was shown that the 
chemotaxis of monocytes, which can occur in response to chemokines from activated 
microglia and astrocytes in the brain can be attenuated by Curcumin.26 
In a recent work16 an in vitro model of Aβ fibrillization was used to show that 
Curcumin can bind amyloid to inhibit Aβ aggregation as well as fibril and oligomer 
formation with dosing at achievable levels. It was demonstrated that Curcumin can 
label plaques in vitro and in vivo, block toxic oligomers in vitro and significanty reduce 
amyloid levels in aged Tg2576 mice (22 months) fed Curcumin diet beginning at 17 
months after established amyloid deposition. Nevertheless it remained unclear from 
which Curcumin activity the amyloid supressing function is achieved. It was 
discovered that Congo Red which inhibits Aβ42 fibrilloginesis and oligomer formation 
through β-sheet breaking,179 its derivative chrysamine G, and RS-0406 a novel  
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Aβ-aggregation inhibitor (Fig. 36) and Curcumin are similar in activity since all bind to 
plaques, prevent oligomer formation at similar low ID50, and recognize secondary 
structure in fibrillar and oligomeric Aβ. 
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Fig. 36  Structures of Curcumin, Congo Red and related molecules.
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The advantage of Curcumin is to be more brain-permeable than these other 
molecules and therefore able to cross the blood-brain barrier easier to bind to plaque 
in vitro.16 The ELISA and aggregation studies showed that Curcumin was able to 
inhibit aggregation or promote Aβ-fibril disaggregation at low concentrations (IC50= 
0.81-1μM) and monomeric Aβ formed fewer aggregates in the presence of Curcumin. 
Higher doses of Curcumin promoted disassembly of performed Aβ aggregates. In 
that work it was also suggested that the effect of Curcumin did not depend on Aβ 
sequence, but on fibril-related conformation and they tested the Curcumin chelation 
of both iron and copper, which was proposed as one mechanism potentially 
contributing to amyloid reduction in animal models. It remained still unclear whether 
Curcumin´s avidity for copper and potential concentration in the brain will be high 
enough to directly alter central nervous system Aβ metal binding. Besides the recent 
evaluations of Curcumin´s potencies to decrease Aβ amyloid burden, and promoting 
disaggregation of Aβ-fibrils to reduce the ongoing causes for β-amyloid induced 
neurotoxicity, the real mechanism by which Curcumin is able to develop its properties 
remain unclear, and research in vivo for achieving more knowledge about this 
compount is necessary. Amyloid accumulation begins decades before diagnosis and 
 68 
therefore anti-amyloid therapie should ideally start before clinical symptoms but also 
efficious approaches at advanced stages of amyloid accumulation are needed. In 
vivo test suggest that Curcumin could be beneficial even after the disease has 
developed.16 
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5. DISCUSSION & FUTURE PERSPECTIVES 
 
 
A wealth of studies from laboratories all over the world support the amyloid 
hypothesis after it has become the focus of extensive AD research over 10 years 
ago.6 According to the amyloid hypothesis that accumulation of Aβ in the brain is the 
primary influence in driving the pathogenesis and the resulting disease process is 
derived through an imbalance between Aβ-production and Aβ-clearance,19, 26 
resulting in chronic-inflammation,140 oxidative damage and following neurotoxicity,37 
various therapeutic strategies have been proposed for treating and preventing the 
pathogenesis so far. Even if to date some treatment strategies which show good 
influence on AD progress are available,6, 180 there are a lot of problems to overcome. 
Currently used NSAIDs are still a matter of debate, not only because of their side-
effects in producing gastrointestinal problems. Furthermore, tested dyes that 
demonstrated to exhibit strong potencies as anti-aggregates showed bad membrane 
permeability in vitro and therefore obtain bad bioavailability and other tested targets 
did not show the expected results or failed in in vitro testing.181 
Nevertheless the development of anti-Aβ aggregation therapeutics remains a rational 
approach for treating AD and other amyloid influenced pathologies. What we need is 
a potent orally available inhibitor of Aβ-amyloidogenesis, that is small enough to 
cross the blood brain barrier, and big enough to interfere with the big β-sheet 
conformation of the fibrils.181 Considering the multifactoral process in AD it is obvious, 
that the therapeutic targets do not adress only one event. Thus, there is a need to 
develop compounds, small molecule mimetics, that adress multiple underlying 
disease mechanisms in parallel, and a multifaceted therapeutic strategy will be 
required for the successful treatment of AD.32 However, to develop a potent anti-
aggregate target the describing and understanding of the exact kinetic mechanisms 
of amyloid fibril-formation and the binding of Curcumin, dyes and other potent 
molecules to the fibrils is primary important. Since this is still far from clear a lot of 
further elaboration in vitro and in vivo are necessary to develop a potential, safe and 
very non toxic anti-amyloidoginesis agent for treating AD and other Aβ-derived 
neurodegenerative disorders. In the old traditional drug Curcumin exhibiting a broad 
range of activity research hope to find a potential candidate. 
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 6. SUMMARY 
 
 
Alzheimer´s disease represents the most common and devasting neurological 
disorder and research is concentrated in finding new potential candidates that not 
only temporarily relieve some symptoms but address the pathological process. 
Knowing that the crucial event of the pathogenesis is the amyloid aggregation 
research was concentrated on molecules that possess multifaceted activity, are small 
enough to cross the blood brain barrier easily, show good bioavailability and 
additionally desirable have no side effects and less toxicity. During the last years of 
research it became increasingly clear that dyes acting as markers for amyloid fibrils 
also exhibit the potency to interfere in the aggregation of ß-amyloid. Curcumin 
promoted in great interest because of its use as a dye and for the treatment of 
several diseases associated with inflammation in Traditional Indian medicine. As it 
was noticed that in India the percentage of AD affected persons is only a quarter to 
that in the US Curcumin was started to be intensively examined whether it exhibits 
features to represent a candidate for a potent anti aggregative agent. 
 
In this work the most important biological activities as well as the chemistry and 
synthesis of Curcumin and the SAR of selected derivatives are exemplified. 
Furthermore, the pathophysiological and clinical principles of AD and the assumption 
of its beginnig and possible mechanisms which are thought to induce the 
pathogenesis of AD are briefly explained. Notabely the so far supposed influence of 
NSAIDs, Curcumin and other dyes on the onset and progression is explicated. 
Summing up the findings of the literature research it could be seriously assumpted 
that Curcumin with its broad range of activitiy and its derivatives opens an interesting 
perspective as possible AD treatment candidates in the future. 
 
So far further investigations are necessary to clearify the exact physiological and 
pharmacokinetical role of Curcumin in Aβ-aggregation and contemporary findings 
could be helpful in the search of new compounds for the treatment and prevention of 
AD and other Aβ aggregation induced CNS disorders. 
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